

**HAWAII BOARD OF OPTOMETRY**  
Professional and Vocational Licensing Division  
Department of Commerce and Consumer Affairs  
State of Hawaii

**AGENDA**

**Date:** August 11, 2025

**Time:** 9:00 a.m.

**In-Person Meeting Location:** Queen Liliuokalani Conference Room  
HRH King Kalakaua Building  
335 Merchant Street, First Floor  
Honolulu, Hawaii 96813

**Virtual Participation:** Virtual Videoconference Meeting - Zoom Webinar  
(use link below)  
[https://dcca-hawaii-  
gov.zoom.us/j/85298838438?pwd=UVOajBhN3ZalU1jbX2fYabxv  
WgHquY.1](https://dcca-hawaii.gov.zoom.us/j/85298838438?pwd=UVOajBhN3ZalU1jbX2fYabxvWgHquY.1)

**Phone:** 1+ 669 900 6833

Meeting ID: 852 9883 8438

Passcode: 434309

**Agenda:** Posted on the State electronic calendar as required by  
Hawaii Revised Statutes ("HRS") section 92-7(b).

If you wish to submit written testimony on any agenda item, please email your testimony to [optometry@dcca.hawaii.gov](mailto:optometry@dcca.hawaii.gov) or submit by hard copy mail to: Attn: Hawaii Board of Optometry, P.O. Box 3469, Honolulu, HI 96801. We request submission of testimony at least 24 hours prior to the meeting to ensure that it can be distributed to the Board members.

**INTERNET ACCESS:**

To view the meeting and provide live oral testimony, please use the link at the top of the agenda. You will be asked to enter your name. The Board requests that you enter your full name, but you may use a pseudonym or other identifier if you wish to remain anonymous. You will also be asked for an email address. You may fill in this field with any entry in an email format, e.g., \*\*\*\*\*@\*\*\*mail.com.

Your microphone will be automatically muted. When the Chairperson asks for public testimony, you may click the Raise Hand button found on your Zoom screen to indicate that you wish to testify about that agenda item. The Chairperson will individually enable each testifier to unmute their microphone. When recognized by the Chairperson, please unmute

your microphone before speaking and mute your microphone after you finish speaking.

#### **PHONE ACCESS:**

If you cannot get internet access, you may get audio-only access by calling the Zoom Phone Number listed at the top on the agenda.

Upon dialing the number, you will be prompted to enter the Meeting ID which is also listed at the top of the agenda. After entering the Meeting ID, you will be asked to either enter your panelist number or wait to be admitted into the meeting. You will not have a panelist number. So, please wait until you are admitted into the meeting.

When the Chairperson asks for public testimony, you may indicate you want to testify by entering “\*” and then “9” on your phone’s keypad. After entering “\*” and then “9”, a voice prompt will let you know that the host of the meeting has been notified. When recognized by the Chairperson, you may unmute yourself by pressing “\*” and then “6” on your phone. A voice prompt will let you know that you are unmuted. Once you are finished speaking, please enter “\*” and then “6” again to mute yourself.

For both internet and phone access, when testifying, you will be asked to identify yourself and the organization, if any, that you represent. Each testifier will be limited to five minutes of testimony per agenda item.

If connection to the meeting is lost for more than 30 minutes, the meeting will be continued on a specified date and time. This information will be provided on the Board’s website at

[http://cca.hawaii.gov/pvl/boards/optometry/meeting\\_schedule/](http://cca.hawaii.gov/pvl/boards/optometry/meeting_schedule/).

Instructions to attend State of Hawaii virtual board meetings may be found online at <https://cca.hawaii.gov/pvl/files/2020/08/State-of-Hawaii-Virtual-Board-Attendee-Instructions.pdf>.

1. Call to Order
2. Approval of Open and Executive Session Minutes of February 10, 2025

The Board may enter into Executive Session to consult with the Board’s attorney on questions and issues pertaining to the Board’s powers, duties, privileges, immunities, and liabilities in accordance with HRS section 92-5(a)(4) to review the executive session minutes.

3. Chapter 91, HRS, Adjudicatory Matters

- A. In the Matter of the Optometrist’s License of Lizeth R. Delgado, O.D., Settlement Agreement Prior to Filing of Petition for Disciplinary Action and Board’s Final Order, OPT 2025-0003-L

- B. In the Matter of the Optometrist's License of Akshay Sanjay Patil; Settlement Agreement Prior to the Filing of Petition for Disciplinary Action and Board's Final Order, OPT 2025-011-L

4. Applications

The Board may enter into Executive Session pursuant to Hawaii Revised Statutes §§ 92-5(a)(1) and 92-5(a)(4) to consider and evaluate personal information relating to individuals applying for professional or vocational licenses cited in section 26-9 or both and to consult with the board's attorney on questions and issues pertaining to the board's powers, duties, privileges, immunities, and liabilities.

A. Ratifications

Approved for DPA License

OD1051	MELANIE DACANAY
OD1052	TINA GIANG
OD1053	ANTHONI NAPPI
OD1055	SOPHIA MOH
OD1056	CORRINE BACHER
OD1057	MICHAEL SIEBERT
OD1058	ALYSSA CHOW
OD1059	JENEE' BROWN
OD1060	MARQUES BOSTIC

Temporary Military/Military Spouse DPA License

OD1054	STEPHEN WELLS
--------	---------------

Approved for TPA Certification

OD1048	SARA FRYE
OD1056	CORRINE BACHER
OD1059	JENEE' BROWN
OD1060	MARQUES BOSTIC

License Restoration

None

5. Continuing Education

A. New Course Requests

INDEX #	PROGRAM TITLE	SPONSOR'S NAME	DATE	LOCATION	HOURS REQUESTED	TPA HOURS REQUESTED
25-006	New Developments in Corneal and Lens Technology	Aloha Laser Vision	3.18.2025 4.15.2025 5.13.2025	Honolulu	1	1
25-007	Meeting the Unmet Needs for Pseudophakic Glaucoma Patients	Hawaii Vision Specialists	3.5.2025	Hilo	1	1
25-008	Update on MIGS & Interventional Glaucoma	Jenkins Eye Care	2.11.2025	Zoom	1	1
25-009	Adjustable IOLs: Reshaping the Refractive surgery Landscape	Jenkins Eye Care	3.27.2025	Zoom	1	1
25-010	Hawaii Optometric Association Live Virtual CE	Hawaii Optometric Association	4.27.2025	Honolulu	4	4
25-011	Minimally Invasive Drop Instillation for Continuing Glaucoma Care	Hawaii Vision Specialists	6.5.2025	Hilo	2	2
25-012	A Year with iDose: Moving Beyond the Traditional Eye Drops	Hawaii Vision Specialists	7/17/2025	Hilo	2	2
25-013	Refractive Technology and Co-Management Update 2025	Aloha Laser Vision	8/20/2025	Honolulu	1	1
25-014	Hawaii Optometric Association Live Virtual CE	Hawaii Optometric Association	9/21/2025	Honolulu	4	4

6. New Business

A. Request for Trade Name

- i. Simply Eyes of Hawaii, LLC  
Tracie Inouchi, OD-571  
Sherry S.Y. Wong, OD-536

B. COPE Annual Report – Information Only



C. Modernization Efforts at NBEO – Information Only

7. 2025 Legislature

A. SB1373 SD2 HD2 CD1: Relating to Administrative Licensure Actions Against Sex Offenders

Authorizes the Department of Commerce and Consumer Affairs and certain licensing boards to automatically revoke and refuse to renew, restore, or reinstate the professional licenses or certification of registered sex offenders.

This bill was signed into law on July 2, 2025 (Act 273, SLH 2025), effective July 1, 2025.

8. Next Board Meeting

Monday, November 10, 2025

9:00 a.m.

Virtual Videoconference Meeting – Zoom Webinar

And

In-Person Meeting Location: PVL Exam Room 330  
HRH King Kalakaua Building  
335 Merchant Street, Third Floor  
Honolulu, Hawaii 96813

9. Election of Officers

- i. Chair
- ii. Vice-Chair

10. Adjournment

*If you need an auxiliary aid/service or other accommodation due to a disability, contact Kerrie E. Shahan at (808) 586-2705 and [optometry@dcca.hawaii.gov](mailto:optometry@dcca.hawaii.gov) of the Hawaii Board of Optometry as soon as possible, preferably by Thursday, August 7<sup>th</sup>. Requests made as early as possible have a greater likelihood of being fulfilled.*

*Upon request this notice is available in alternate/accessible formats.*

08/05/2025

**HAWAII BOARD OF OPTOMETRY**  
Professional and Vocational Licensing Division  
Department of Commerce and Consumer Affairs  
State of Hawaii

**MINUTES OF MEETING**

Date: February 10, 2025

Time: 9:00 a.m.

Place: Queen Liliuokalani Conference Room  
HRH King Kalakaua Building  
335 Merchant Street, First Floor  
Honolulu, Hawaii 96813

Virtual Videoconference Meeting – Zoom Webinar  
<https://dcca-hawaii-gov.zoom.us/j/84327053409?pwd=xbehP7S7dsO5WkjbjtqxfHZ086cy75.1>

Zoom Recording Link [https://youtu.be/Hgl\\_R\\_1pQvg](https://youtu.be/Hgl_R_1pQvg)

Present: K. Paul Chin, O.D., Chairperson (“Chair”)  
Peter Clayton Searl, O.D., Vice-Chairperson (“VC”)  
Gayle Chang, Public Member  
Wallace Kojima, O.D (Virtual)

Excused: None

Staff: Andrew I. Kim, Deputy Attorney General (“DAG”)  
Kerrie Shahan, Executive Officer (“EO”)  
Dawn Lee, Secretary  
Johnny Li, Tech Support

Guests:

Agenda: The agenda for this meeting was posted on the State electronic calendar as required by HRS section 92-7(b).

A short video was played to explain the meeting procedure and how members of the public could participate in the virtual meeting.

1. Call to Order: Chairperson Chin welcomed everyone to the meeting and proceeded with a roll call of the Board members. Board members joining via Zoom confirmed that they were present and alone.

There being a quorum present, Chair Chin called the meeting to order at 9:08 a.m.

2. Approval of  
Board Minutes  
Of November 18,  
2024

Chair Chin inquired if anyone would like to provide public testimony regarding the agenda item for approving the Board Meeting Minutes. Since no one came forward, he then asked the Board members if they had any corrections or amendments to the minutes. With no corrections offered, he requested a motion to approve the minutes. It was moved by Ms. Chang and seconded by Vice Chair Searl. The motion to approve the open session Board meeting minutes from November 18, 2024, as circulated, was without objections. The motion was unanimously carried.

3. Applications

a. Ratifications

Approved for DPA Certification

OD1047	ELISA HEARN
OD1048	SARA FRYE
OD1049	JERRY NAVE
OD1050	YANLEI WU

Approved for TPA Certification

OD290	JON SAKUDA
OD1047	ELISA HEARN

License Restoration

Chair Chin inquired if anyone would like to provide public testimony regarding the agenda item concerning the approval of DPA and TPA Certifications. Since there were no objections, he requested a motion to ratify the approved applications. The motion was moved by Vice Chair Searl and seconded by Ms. Chang. He then asked if there were any objections. As there were no objections, the motion to ratify the applications was approved.

4. Request for  
CE Program  
Approval

a. New Course Request

Chair Chin inquired if anyone would like to provide public testimony regarding the agenda item concerning the request for approval of these Continuing Education "CE" programs. Since there were no objections, he requested a motion to approve the CE programs. The motion was moved by Ms. Chang and seconded by Dr. Kojima. He then asked if there were any objections. As there were no objections, the motion to approve the following CE programs:

INDEX #	PROGRAM TITLE	SPONSOR'S NAME	DATE	LOCATION	HOURS REQUESTED	TPA HOURS REQUESTED
25-001	Review of Cataract Surgery and Advancements in Intraocular Lens Options	Jenkins Eye Care	10.24.2024	Honolulu/Zoom	1	1
25-002	Updated Options in Keratoconus	Aloha Laser Vision	01.08.2025	Honolulu/Zoom	1	1
25-003	17 <sup>th</sup> Annual Optometric CE in Paradise	Jenkins Eye Care	11.21.2024	Honolulu	2	2
25-004	VSP Premier Edge +PECAA – Mahalo 2025	VSP Vision	5.8.2025	Kapolei	4	3

b. Email from Hawaii Vision Specialists

Chair Chin stated that Hawaii Vision Specialists contents that an application and check were previously sent in for a course to be offered on July 25, 2024; however, due to loss or another issue, the Board did not receive it. According to Hawaii's law, the Board has 45 days to approve applications, but due to our meeting schedule, that 45-day period can pass quickly. As a result, they have submitted a request and have re-applied for the hours. He does not remember all the details.

Ms. Shahan stated that the class entitled "Interventional Glaucoma Advances: Eye Stent and Eye Dose" was offered by Hawaii Vision Specialist on July 25.

Chair Chin stated that the CE program is for two hours of TPA credit. The discussion focuses on the fact that this situation has occurred before, and in the past, the board has granted requests after conducting due diligence for various reasons. Chair Chin noted that the 45-day timeline can be challenging; often, by the time one figures everything out. This might be a topic for the board to revisit at a later date regarding the 45-day deadline. Chair Chin then requested a motion to approve this CE programs for two hours with Hawaii Vision Specialists. The motion was moved by Vice Chair Searl and seconded by Dr. Kojima. He then asked if there were any objections. As there were no objections, the motion to approve this CE was approved.

c. Email from Jan Murray Executive Officer, Kansas Board of Examiners in Optometry

Chai Chin stated that the Board received a letter from the Kansas Board of Examiners regarding the eight hours of DEA training, confirming that it can count towards continuing education (CE). After some research, it was found

that the DEA classes are equivalent to COPE classes, and in fact, they do accept COPE classes for DEA certification. He asked the other Board members if they had any thoughts or discussions on this matter. After digging deeper, he noted that since the DEA accepts COPE hours, it seemed plausible to move forward, although approvals would likely be handled on a case-by-case basis. It is important to mention that there is not an official transcript for these hours. In his opinion, the process would be similar assessing individual courses, such as Jenkins, where hours are reviewed on a case-by-case manner based on the sponsoring organization. Since organizations like the AMA, COPE, NURSIS sponsor these courses, the acceptance would depend on who is sponsoring the training. He does not foresee any issues with this approach. Chair Chin emphasized the importance of remaining open to changes, as the profession is evolving. He noted that in some states, possessing an opioid DEA registration is now a requirement for continuing education. He does not want to hinder current progress by rejecting these opportunities now, especially as circumstances may change in the future. Chair Chin request Board Member to share any thoughts or discussion points, as they have asked us to draft a letter.

Ms. Shanhan confirmed Chair Chin's statement that the Kansas Board of Examiners and Optometry is inquiring whether we would accept those hours. A letter will be drafted informin the Kansas Board on this Boards determination.

Vice Chair Searl inquired whether the individual completing the course would submit documentation confirming their participation in the DEA training related to opioids.

Chair Chin confirmed the statement and mentioned that he does not view the situation as significant because it is Kansas that is making the request, not us. He indicated that while it might arise again in the future, it would be beneficial for our board to address it now.

Dr. Kojima believes that decisions should be made case-by-case, similar to any other courses, provided that the Board receives a syllabus detailing their activities.

Chair Chin requested a motion to approve the DEA opioid classes for continuing ed on a case-by-case basis, going forward. The motion was moved by Dr. Kojima and seconded by Vice Chair Searl. He then asked if there were any objections. As there were no objections, the motion to approve the DEA opioid classes for continuing ed on a case-by-case basis.

Staff was directed to send a letter to the Kansas Board of Optometry with this information.

d. 2025 Optometrists Renewal Information for Website

A draft of the continuing education for renewal was distributed to Board members for review and approval.

Dr. Kojima stated that for COPE Categories, the PH, Pharmacology under DPA should be classified under the TPA.

Ms. Shahan agreed with Dr. Kojima that it was placed in the wrong column. The PH, Pharmacology and SD, Systemic Diseases should be listed under TPA.

Vice Chair Searl inquired whether the NO, Neuro-Optometry should also be in the TPA column and also wondered if concussion was considered Nero at all.

Ms. Shahan confirmed that the Board has consistently categorized Neuro-Optometry under TPA. She is uncertain whether Neuro-Optometry specifically covers concussions; however, the Board has previously discussed concussions and brain injuries and determined that these topics would be approved as a TPA course (even if it was listed as general optometry, if it related to concussions, the board determined that they would use it for TPA). Ms. Shahan asked the Board if the corrections regarding pharmacology and systemic diseases were properly categorized. If everything else looks satisfactory, we can proceed with posting the information on the website.

Chair Chin acknowledged it was acceptable to proceed and thanked Dr. Kojima for pointing that out.

5. New Business

a. Request for Trade Name – Ratification

- i. Reynolds Optometric  
Geoffrey Reynolds, OD-491

Chair Chin inquired if anyone would like to provide public testimony regarding the agenda items concerning new business. No requests for testimony were made. The first item on the agenda is a request for trade name ratification for "Reynolds Optometric" submitted by Dr. Geoffrey Reynolds. The Board then requested to consult with DAG Kim.

It was moved by Ms. Chang, seconded by Vice Chair Searl, and unanimously carried to enter into executive session at 9:23 a.m., pursuant to HRS §92-5(a)(1), to consider and evaluate personal information relating to individuals applying for professional licenses cited in HRS §26-9 and, pursuant to HRS §92-5 (a)(4), to consult with the Board's attorney on questions and issues

pertaining to the Board's powers, duties, privileges, immunities and liabilities.  
(Note: Board members and staff entered the Zoom Breakout Room).

#### EXECUTIVE SESSION

At 9:34 a.m. Board members and staff returned to the main Zoom meeting.  
All Board members confirmed that they were present and alone.

Chair Chin stated that the Board sees no problem with the request from Reynolds Optometric. The motion was made by Dr. Kojima and seconded by Vice Chair Searl. Chair Chin asked if there were any objections. As there were no objections, the motion to ratify "Reynolds Optometric" was passed.

b. Email from Inna Litvin, OD-899

- i. Are TPA-certified optometrists allowed to use Low-Level Light (LLLT) Therapy for dry eye management?
- ii. Are TPA-certified optometrists allowed to use IPL (MDelite/Infinity Pro) to treat dry eye?
- iii. Are TPA-certified optometrists allowed to use the Allerfocus allergy testing kits to test for allergic conjunctivitis?

Chair Chin explained that the Board has not established guidelines for every treatment, diagnostic procedure, or new machine that emerges. Traditionally, when there are no specific guidelines available, the Board has operated under the principle that "our rules are silent on these procedures." Chair Chin then asked if any other Board members wished to discuss the matter further.

Dr. Kojima expressed his agreement with Chair Chin's statement, as in the previous meeting, the Rules tend to remain silent on many issues. He mentioned that most topics would be acceptable unless they were examined in great detail. Additionally, Dr. Kojima has consistently received injections and other treatments outside of school.

Chair Chin requested a motion to send a letter to the licensee addressing her questions about low-level light therapy and allergy testing. The motion was moved by Dr. Kojima and seconded by Vice Chair Searl. He then asked if there were any objections. As there were no objections, the motion was

6. 2025 Legislature a. SB1373: Relating to Administrative Licensure Actions Against Sex Offenders

Authorizes the Department of Commerce and Consumer Affairs and certain licensing boards to automatically revoke and refuse to renew, restore, or reinstate the professional licenses of registered sex offenders.

Chair Chin noted that the relevant section of SB1333 is found in section one on page 50. Staff provided testimony to the Senate Consumer Protection Committee on behalf of the Board on February 4<sup>th</sup> which stated that while the Board had not yet reviewed the bill, in the past the Board has been supportive of measures that protect the public interest and welfare. The bill has been passed, with amendments which have not yet been posted.

Ms. Shahan noted section 21 of SB1373 specifies that, notwithstanding any contrary laws, the Board of Optometry shall automatically revoke a license or deny any application to renew, restore, or reinstate a license under the following conditions:

- If the licensee has been convicted in any court, whether within or outside the state, of an offense that would place them on the sex offender registry.
- If the licensee is required to register as a sex offender, the Board will not renew, restore, reinstate, or will revoke the license of that individual.

This represents a shift from current practice. Currently, if there are concerns about someone's license, they have the opportunity for a contested case hearing, and their license remains active throughout that process, which can be time consuming. This is justified because individuals have a property interest in their licenses. However, the proposed bill states that if someone is in a profession where they may be alone with a person in an enclosed space, or if their services require physical contact with a person, and they are registered as a sex offender, the safety of the public takes precedence over the individual's license concerns. The person's license can be revoked immediately, but they can later request reinstatement after the Board assesses whether they should retain their license based on their conviction status.

Ms. Shahan provided this testimony before the Senate Committee before the Board had the opportunity to meet. She did not confirm that the Board either supports or opposes the bill. Instead, she mentioned that in the past, the Board has supported legislation that protects consumers. She is seeking guidance from the Board on how to present their position when the bill is discussed again in the next hearing.



Chair Chin asked if any Board members would like to discuss this.

Dr. Kojima stated that he was for it.

Vice Chair Searl inquired about the Board's authority to revoke licenses, noting that in the past, there may have been a possibility for restoration. He would like to confirm if he is interpreting this correctly.

Ms. Shahan stated that upon part C, upon revocation of the license or denial of an application to renew, restore, or reinstate, the licensee may file a written request for a hearing with the licensing authority within 10 days of the notice. The hearing shall be held within 30 days of the revocation or denial and the proceedings shall be conducted in accordance with Chapter 91. So, the person can ask to have the license reinstated.

DAG Kim stated that, essentially, the licensee would no longer be eligible to practice after receiving a sex offender registration.

Vice Chair Searl was curious about why they would request us to review the matter again.

DAG Kim explained that if they were to have their license revoked, current law allows them to reapply after five years. However, this new law states that their application must be denied. Essentially, this means that their license would be revoked permanently.

Chair Chin stated that he has no issues with it either. The Board's role is to protect the public. He asked Ms. Shahan if she would be seeing them again.

Ms. Shahan informed them that the process will involve several hearings, with this being just the first. Both this bill and HB 1054, the House version of the same bill, have been discussed. They will proceed to additional committee reviews. She needs to gather testimony to present to the board regarding whether it is in support of the bill or wants to provide comments. Please indicate how you would like me to convey your position to the legislature. If the board fully supports the bill with no comments, that can be stated. If there are concerns, this is the opportunity to express that, indicating support while also highlighting specific issues. Please direct her on what you would like the committee to know on behalf of this board.

Chair Chin expressed his inclination to fully support the measure. The Board's mandate is to protect the public, and additional comments are unnecessary unless another Board member has something to add. Dr. Kojima concurred.

The Board members confirmed that they supported the measure.

b. HB1054: Relating to Administrative Licensure Actions Against Sex Offenders

Authorizes the Department of Commerce and Consumer Affairs and certain licensing boards to automatically revoke and refuse to renew, restore, or reinstate the professional licenses of registered sex offenders.

Ms. Shahan noted that this is the companion bill to SB 1373 and requested clarification from the Board regarding the direction they are giving her for SB 1373, which is the same direction they have for House Bill 1054.

Chair Chin confirmed that this was accurate for both the Senate and the House.

c. Legislative Liaison(s)

The Board will consider appointing legislative liaisons(s) to provide positions and testify on legislative proposals.

Chair Chin stated that they should consider appointing legislative liaisons. Items like this may arise occasionally. Ms. Shahan is requesting one or two volunteers.

Ms. Shahan confirmed that there will be one or two volunteers involved. She emphasized the importance of keeping the group small to avoid violating the Sunshine Law, which could occur if a quorum is reached. The volunteers are needed to provide feedback; if any significant changes are made in the next version of the document, she can bring them to the board's attention and ask for their input. As the Board won't meet again until May, and with legislation wrapping up around that time, she doesn't anticipate many changes to the bill. However, in case there are significant modifications, she needs someone to consult with for discussion.

Chair Chin announced that he would take the initiative and volunteer, thereby sparing everyone from the hassle. He requested to know if they should get a second, just in case. Vice Chair Searl volunteered.

7. Next Board Meeting:

Monday, May 12, 2025

9:00 a.m.

In-Person: Queen Liliuokalani Conference Room  
HRH King Kalakaua Building  
335 Merchant Street, Third Floor  
Honolulu, Hawaii 96813

Virtual

Participation: Virtual Videoconference Meeting – Zoom Webinar

9. Adjournment: With no further business to discuss, Chair Chin adjourned the meeting at 9:47 a.m.

Taken by:

Dawn Lee  
Dawn Lee,  
Secretary

Reviewed by:

s/ Kerrie Shahan  
Kerrie Shahan  
Executive Officer

04/14/2025

- [ ] Minutes approved as is.  
[ ] Minutes approved with changes; see minutes of \_\_\_\_\_.

State of Hawaii  
Department of Commerce and Consumer Affairs  
**HAWAII BOARD OF OPTOMETRY**  
335 Merchant St., 3rd Floor, Honolulu, HI 96813  
Mailing Address: P.O. Box 3469, Honolulu, HI 96801  
Access this form via website at: [cca.hawaii.gov/pvl](http://cca.hawaii.gov/pvl)

**PROGRAM SPONSOR AGREEMENT FOR CONTINUING EDUCATION ("CE")**

**PROGRAM TITLE:** New Developments in Corneal and Lens Technology

**INSTRUCTIONS**

1. Submit this original completed application form for each course title no more than 45 days after the course is completed;
2. Attach a program outline including time schedule;
3. Attach course description;
4. Attach curriculum vitae of all lecturer(s);
5. Attach a copy of the certificate of attendance (please see Hawaii Administrative Rules §16-92-40(a) for the required information); and
6. Attach a check for \$25 made payable to: "COMMERCE & CONSUMER AFFAIRS". (check must be in U.S. dollars and be from a U.S. financial institution.)

**FOR OFFICE USE ONLY**

Index number 25006  
Reviewed by P. Chin  
Approved by \_\_\_\_\_  
Amended date \_\_\_\_\_

**SPONSOR'S NAME:** Aloha Laser Vision

**PHONE NO.:** \_\_\_\_\_

**EMAIL ADDRESS:** \_\_\_\_\_

**TYPE OF ORGANIZATION:** Private Ophthalmology Practice

**BUSINESS ADDRESS:** 1100 Ward Avenue Suite 1000; Honolulu, HI 96814

**LOCATION OF PROGRAM (City, State):** Honolulu, HI

**DATE OF PROGRAM:** \_\_\_\_\_

**Total CE hour(s) being requested:** 1


3/18/2025  
4/15/2025  
5/13/2025

1 hours(s) will apply towards fulfilling the 36 hours of CE in the diagnosis, treatment and management of ocular and systemic diseases, required for license renewal of an optometrist with therapeutic pharmaceutical agent ("TPA") certification.

**The sponsor agrees that the program shall be such:**

1. That it will require and monitor the attendance;
2. That it will be at least 50 minutes in duration for each hour claimed from the beginning of the subject matter to its conclusion;
3. That it will be presented by a qualified lecturer, whose name, title, and qualifications are to be included in attached curriculum vitae;
4. That written records of its attendees and of the program outline shall be maintained in its files for a period of two years immediately following its conclusion;
5. That written evidence of attendance will be issued by the Sponsor to **each attendee** with the CE hour(s) and the Board's Hawaii Index Number shown thereon. The Board will not accept any certification of attendance or lists of attendees from the Sponsor. If any are received, they will be discarded;

(CONTINUED ON PAGE 2)



Print Name of Sponsor: Aloha Laser VisionDate: 2/4/2025

6. That the CE hour(s) requested are exclusive of any preparation time;
7. That the program records will be subject to review by the Hawaii Board of Optometry ("Hawaii Board") and the program sponsor agrees to make these records available to the Hawaii Board or its designee during regular business hours at the business address indicated on this application for a period of two years following the date of presentation; and
8. That the Hawaii Board will be notified as to the location of these records if they are removed from the above location prior to expiration of the above two year period.

In consideration for compliance with this agreement, we understand that we may advise prospective attendees of the approval of our program and the number of hours of credit allowable. If we fail to comply with this agreement or fail to meet acceptable standards in our program, we understand that approval of our program may be revoked by the Hawaii Board and that notice of such revocation may be given by the Hawaii Board to all licensees.

By   
Signature of individual responsible for CE administration

2/4/2025  
Date


Its Optometrist  
Title

Kathryn Mau, OD  
Print name of individual responsible for CE administration

(THIS FORM MAY BE DUPLICATED)

Print Form

This material can be made available for individuals with special needs. Please call the Licensing Branch Manager at (808) 586-3000 to submit your request.





**Program: New Developments in Corneal and Lens Technology**

**Program Date: 3/18/2025, 4/15/2025, 5/13/2025**

**Speaker: Alan R. Faulkner, MD**

## **Program Outline and Time Schedule**

5:00 – 5:15 Check-in

5:15 – 6:15 “New Developments in Corneal and Lens Technology” lecture

6:15 – 6:30 Q&A

6:30 End of meeting

## **Course Description**


There are constantly updates to technology in ophthalmology. For keratoconus, epi-on cross-linking is expected to be approved by the FDA within the next year, and Corneal Tissue Additive Keratoplasty (CTAK) is a promising procedure to improve best-corrected visual acuity. For corneal refractive surgery, ray-tracing wavefront LASIK is the newest version of custom LASIK which attempts to correct higher-order aberrations for improved quality of vision. There are also new IOL implants to discuss, such as the Tecnis Odyssey and the enVista Envy, which are the newest additions to our armamentarium of multifocal intraocular lenses.

## **Course Notes**

This live course will be offered on 3 separate dates due to seating limitations. Attendees will only be allowed to attend one of the three dates for CE credit.

1100 WARD AVENUE SUITE 1000 HONOLULU, HAWAII 96814 ✦ PHONE: 808.792.3937 FAX: 808.599.4818

Alan R. Faulkner, MD ✦ Ryan Steck, DO ✦ Kathryn Mau, OD ✦ Elizabeth Hanohano-Hong, OD ✦ Jordan Schmerbauch, OD





**ALAN R. FAULKNER, M.D., F.A.A.O.**

1100 Ward Avenue, Suite 1000

Honolulu, HI 96814  
**EMPLOYMENT HISTORY**

---

Aloha Laser Vision, LLC <i>Founder, Medical Director</i> 1100 Ward Avenue, Suite 1000 Honolulu, HI 96814	Jan 2002 - present
The Surgical Suites, LLC <i>Co-owner, Managing Director</i> 1100 Ward Avenue, Suite 1010 Honolulu, HI 96814	Jan 2005 - present
Faulkner Eye Care & Surgery <i>Ophthalmologist</i> 1100 Ward Avenue, Suite 1000 Honolulu, HI 96814	May 2000 – Dec 2001
Eye Associates of West Jefferson <i>Ophthalmologist</i> 1111 Medical Center Blvd., N-213 Marrero, LA 70072	Aug 1998 – Apr 2000
Medical & Surgery Eye Center <i>Ophthalmologist</i> 1051 Gause Blvd., Suite 480 Slidell, LA 70458	Aug 1998 – Apr 2000
Tulane University Medical School <i>Assistant Professor of Ophthalmology</i> Department of Ophthalmology 1430 Tulane Avenue New Orleans, LA 70131	Jul 1991 – Aug 1998
Valley Supply Company <i>Salesman / Business Owner</i> West Des Moines, IA	Jan 1977 – Aug 1980

**EDUCATION**

---

Northwestern University, Kellogg School of Management Evanston, IL Physician CEO	Sept 2015
Tulane University School of Medicine New Orleans, LA Medical Doctorate	May 1986
University of Hawaii at Manoa Honolulu, HI	May 1982
Northwestern University Evanston, IL B.A. Sociology	Aug 1976



**ACADEMIC APPOINTMENTS**

---

Clinical Assistant Professor of Ophthalmology Tulane Medical School, Department of Ophthalmology	Aug 1998 – May 2000
Assistant Professor of Ophthalmology, Full-time Faculty Tulane Medical School, Department of Ophthalmology	Jul 1991 – Aug 1998

**PROFESSIONAL ASSOCIATIONS**

---

American Academy of Ophthalmology, Fellow  
 American Society of Cataract and Refractive Surgery  
 American-European Congress of Ophthalmic Surgery, Founding Member  
 Hawaii Ophthalmological Society

**PROFESSIONAL ACTIVITIES**

---

Hawaiian Eye Foundation  
 Scientific Advisory Board, 2014 – 2016  
 Board Member, 2016 – present

**INDUSTRY ASSOCIATIONS (current and past)**


---

Acufocus – speaker  
 Alcon – speaker, consultant, research  
 Avedro – consultant  
 Bausch & Lomb – speaker, consultant  
 LenSx – clinical trials  
 Omeros – consultant  
 Refocus – clinical research  
 Shire – speaker  
 Wavetec – speaker, consultant, clinical trials

**PRESENTATIONS and MEETING FACULTY**

---

AECOS Aspen – multiple presentations/panels/multiple meetings  
 AECOS Deer Valley – multiple presentations/panels/multiple meetings  
 ESCRS – numerous presentations of own and for others  
 Hawaiian Eye Meeting – 2013 to present  
 ISRS – AAO 2014  
 National Medical Association – Honolulu Meeting  
 OSN New York – 2012 – 2016  
 OSN Rome/Milan – 2011, 2013 – 2015







# CERTIFICATE OF CONTINUING EDUCATION

This Acknowledges That

<Insert Name Here>

Has Successfully Completed

"New Developments in Corneal and Lens Technology"  
Course ID: XX-XXX, 1 Credit Hour of TPA Certification  
Honolulu, HI (Zoom Live Webinar)

*Alan R. Faulkner MD*

**ALAN R. FAULKNER, MD**

**BOARD CERTIFIED OPHTHALMOLOGIST**






# CERTIFICATE OF CONTINUING EDUCATION

This Acknowledges That

<Insert Name Here>

Has Successfully Completed

"New Developments in Corneal and Lens Technology"  
Course ID: XX-XXX, 1 Credit Hour of TPA Certification  
Honolulu, HI (Zoom Live Webinar)



*Alan R. Faulkner MD*

**ALAN R. FAULKNER, MD**

**BOARD CERTIFIED OPHTHALMOLOGIST**





# CERTIFICATE OF CONTINUING EDUCATION

This Acknowledges That

<Insert Name Here>

Has Successfully Completed

"New Developments in Corneal and Lens Technology"  
Course ID: XX-XXX, 1 Credit Hour of TPA Certification  
Honolulu, HI (Zoom Live Webinar)



*Alan R. Faulkner MD*

**ALAN R. FAULKNER, MD**

**BOARD CERTIFIED OPHTHALMOLOGIST**



**HAWAII BOARD OF OPTOMETRY**

335 Merchant St., 3rd Floor, Honolulu, HI 96813

Mailing Address: P.O. Box 3469, Honolulu, HI 96801

Access this form via website at: [cca.hawaii.gov/pvl](http://cca.hawaii.gov/pvl)

**PROGRAM SPONSOR AGREEMENT FOR CONTINUING EDUCATION ("CE")**

**PROGRAM TITLE:** Meeting the Unmet Clinical Needs for Pseudophakic

*Glaucoma Patients*

**INSTRUCTIONS**

1. Submit this original completed application form for each course title no more than 45 days after the course is completed;
2. Attach a program outline including time schedule;
3. Attach course description;
4. Attach curriculum vitae of all lecturer(s);
5. Attach a copy of the certificate of attendance (please see Hawaii Administrative Rules §16-92-40(a) for the required information); and
6. Attach a check for \$25 made payable to: "COMMERCE & CONSUMER AFFAIRS". (check must be in U.S. dollars and be from a U.S. financial institution.)

**FOR OFFICE USE ONLY**

Index number \_\_\_\_\_

Reviewed by \_\_\_\_\_

Approved by \_\_\_\_\_

Amended date \_\_\_\_\_



**SPONSOR'S NAME:** Hawaii Vision Specialists

**PHONE NO.:** 808-333-3233

**EMAIL ADDRESS:** info@hawaiivisionspecialists.com

**TYPE OF ORGANIZATION:** Ophthalmology and Optometry Practice

**BUSINESS ADDRESS:** 392 Kapiolani St, Hilo HI 96720

**LOCATION OF PROGRAM (City, State):** Hilo, HI

**DATE OF PROGRAM:** 3/5/2025

**Total CE hour(s) being requested:** 1

1 hours(s) will apply towards fulfilling the 36 hours of CE in the diagnosis, treatment and management of ocular and systemic diseases, required for license renewal of an optometrist with therapeutic pharmaceutical agent ("TPA") certification.

**The sponsor agrees that the program shall be such:**

1. That it will require and monitor the attendance;
2. That it will be at least 50 minutes in duration for each hour claimed from the beginning of the subject matter to its conclusion;
3. That it will be presented by a qualified lecturer, whose name, title, and qualifications are to be included in attached curriculum vitae;
4. That written records of its attendees and of the program outline shall be maintained in its files for a period of two years immediately following its conclusion;
5. That written evidence of attendance will be issued by the Sponsor to **each attendee** with the CE hour(s) and the Board's Hawaii Index Number shown thereon. The Board will not accept any certification of attendance or lists of attendees from the Sponsor. If any are received, they will be discarded;


(CONTINUED ON PAGE 2)

Print Name of Sponsor: Hawaii Vision Specialists

Date: 3/5/2025 25-007

6. That the CE hour(s) requested are exclusive of any preparation time;
7. That the program records will be subject to review by the Hawaii Board of Optometry ("Hawaii Board") and the program sponsor agrees to make these records available to the Hawaii Board or its designee during regular business hours at the business address indicated on this application for a period of two years following the date of presentation; and
8. That the Hawaii Board will be notified as to the location of these records if they are removed from the above location prior to expiration of the above two year period.

In consideration for compliance with this agreement, we understand that we may advise prospective attendees of the approval of our program and the number of hours of credit allowable. If we fail to comply with this agreement or fail to meet acceptable standards in our program, we understand that approval of our program may be revoked by the Hawaii Board and that notice of such revocation may be given by the Hawaii Board to all licensees.

By   
Signature of individual responsible for CE administration

3/5/2025

Date

Its ophthalmologist/optometrist  
Title

Dan Driscoll, MD/Jana Souza, OD

Print name of individual responsible for CE administration

**(THIS FORM MAY BE DUPLICATED)**

**Print Form**

This material can be made available for individuals with special needs. Please call the Licensing Branch Manager at (808) 586-3000 to submit your request.



## Meeting The Unmet Clinical Needs For Pseudophakic Glaucoma Patients: A One-Hour Presentation

Presented by Speaker Dan Driscoll, MD

03/05/2025


Target audience will be optometrists and medical ophthalmologists in the community who are interested in learning more about how to correctly diagnose and recommend treatments for patients that have glaucoma and that are also pseudophakic.

The presentation will focus on glaucoma as the second leading cause of blindness worldwide impacting nearly 4 million patients in the United States and not having any specific cure. There is a substantial number of patients in the general populace that have already had cataract surgery and are looking for additional ways to help manage their glaucoma through means other than having additional eye drops as part of their therapy. This can typically happen somewhere around the 3-to-7-year mark after the patient has already had an intervention at the time of cataract surgery involving a likely minimally invasive glaucoma surgery (MIGS).

We are well aware that taking topical glaucoma drops has a very low potential for 100% compliance rate due to several factors that we will discuss impairing the ability for patients to take their medications reliably. There had been studies including the glaucoma adherence and persistent study (GAPS) showing that only about 10% of patients have medication available and a very high percentage of these patients discontinue therapy after only one month of use. This does promote it being a very difficult condition to treat reliably when clinicians are relying on patients to take their medications.


We also know that for any intraocular pressures higher than 18, there can be substantially impaired field of vision and every millimeter mercury above 18 can cause significant progression in visual field defects. The goal for most clinicians at this point is to have earlier intervention for glaucoma patients to reduce the potential level of visual disability and hopefully stave off any additional larger interventions such as tube shunt surgeries and/or trabeculectomies which can be fraught with significant complication and comorbidity.

One device specifically called the Omni is known to address 3 areas of resistance including the trabecular meshwork, Schlemm's canal, and collector channels and this is a very unique feature to this device being able to offer patients that are already pseudophakic additional options for treatment. Typically, patients tolerate this procedure quite well and can have remarkable reductions in intraocular pressure and therefore reduction in the drop burden which can improve their overall quality of life which can translate into better functional vision.





<b>Education</b>	08/02 - 06/06	<i>The Ohio State University College of Medicine and Public Health.</i> Columbus, Ohio. Doctor of Medicine, Magna Cum Laude
	08/98 - 05/02	<i>Case Western Reserve University.</i> Cleveland, Ohio. Bachelor of Science, Biochemistry, Summa Cum Laude
<b>Professional Training</b>	07/10- 07/11	Cornea Fellowship. <i>Bascom Palmer Eye Institute.</i> Miami, Florida
	07/07 - 06/10	Ophthalmology Residency. <i>Bascom Palmer Eye Institute.</i> Miami, Florida
	06/06 - 06/07	Transitional Year Residency. <i>Mercy Hospital Pittsburgh.</i> Pittsburgh, Pennsylvania
<b>Professional experience</b>	01/12-present	Cornea, Cataract, and Refractive Surgeon. Hawaii Vision Specialists, Hilo, Hawaii Specializing in cataract and refractive lens surgery, all-laser refractive surgery, DSAEK and cornea transplant surgery, as well as comprehensive ophthalmology including glaucoma, oculoplastic, and medical retina care
	08/11-12/11	Cornea, Cataract, and Refractive Surgeon. Southeast Eye, Brunswick, GA Performed specialty cataract and refractive lens surgery, all-laser refractive surgery, DSAEK and cornea transplant surgery.
<b>Academic Societies</b>		American Academy of Ophthalmology American Society of Cataract and Refractive Surgery
<b>Licensure</b>		Hawaii License MD16407 valid through 01/31/2018
<b>Board Certification</b>		American Board of Ophthalmology Board Certified 06/2012 through 06/2022
<b>Volunteer Work and Community Service</b>	2012-present	Project Vision: Community vision screenings with coordinated effort from Hawaii Lions Clubs on the island of Hawaii. Locations have included Hilo, Waimea, Ka'u
<b>Publications and Presentations</b>		Driscoll, D. <i>All You've Ever Wanted to Know about Eyes (from audience-submitted questions) (2 hours).</i> Hilo Bay Café, Hilo, Hawaii. July 15, 2017.
		Driscoll, D. <i>Glaucoma Update (2 hours).</i> Hilo Bay Café, Hilo, Hawaii. July 08, 2016.
		Driscoll, D. <i>Retina, Glaucoma, and Cataract Update.</i> 4 hour Presentation for Continuing Education for the Hawaiian Optometric Association's annual state meeting. Mauna Lani Resort, Waikaloa, HI. November 1, 2015.
		Driscoll, D. <i>Ophthalmic Medical and Surgical Update (2 hours).</i> Restaurant Miwa, Hilo, HI. July 10, 2015.
		Driscoll, D. <i>Evaluation and Management of Common Ophthalmic Conditions (1 hour).</i> Hilo Medical Center Continuing Medical Education Seminar, Hilo, Hawaii. October, 11, 2014.
		Driscoll, D. <i>Interesting Cases in Ophthalmology (2 hours).</i> Hilo Bay Café, Hilo, Hawaii. August 21, 2014.



Driscoll, D. *Ophthalmic Update for Community Optometrists (3 hours)*. Imiloa Astronomy Center, Hilo, Hawaii. September 27, 2013.

Driscoll, D. Lam, B. *The effect of resistance training on microsurgical tremor: Incorporation of Pharmacologic Intervention*. Bascom Palmer Eye Institute Residents Day, 2011. Miami, Florida. June 17, 2011.

Driscoll, D. *International Ophthalmology Experiences*. Speaking presentation at Bascom Palmer weekly Cornea Conference. Bascom Palmer Eye Institute. May 11, 2011

Driscoll, D. *Corneal Topography for Residents*. Speaking presentation at weekly resident's conference. Bascom Palmer Eye Institute, November 23, 2010.

Driscoll, D. *What a cornea fellowship-trained ophthalmologist can offer to a referring optometrist*. SouthEast Eye Annual Fall Conference, St. Simons Island, Ga. September 25, 2010.

Driscoll, D. *Visual outcomes after wavefront-guided photorefractive keratectomy and wavefront-guided laser in situ keratomileusis: Prospective comparison*. Discussed in detail at Bascom Palmer Department of Cornea Refractive Journal Club. August 30, 2010.

Driscoll, D. *Manual Small Incision Cataract Surgery as an Alternative to Phacoemulsification in Dense Nuclear Sclerotic Cataracts*. Bascom Palmer Eye Institute Grand Rounds. Discussant Charlie Wykoff, MD, PhD. July 8, 2010.

Driscoll, D. Lam, B. *The effect of resistance training on microsurgical tremor*. Bascom Palmer Residents Day 2010. Miami, Florida. June 18, 2010.

Driscoll, D, Yoo S. *SubTenons Ranibizumab for the Inhibition of Neovascularization in the Cornea in High Risk Corneal Transplant Surgery*. Speaking presentation, ASCRS Boston. April 12, 2010.

Driscoll, D. *Intraorbital Cavernous Hemangioma; Management and Operative Options*. Bascom Palmer Eye Institute Grand Rounds. Discussant Chris Alabiad, MD. March 10, 2010

Driscoll, D. *Aspergillus keratitis requiring emergency penetrating keratoplasty: Investigation of current pharmacologic susceptibilities*. Bascom Palmer Eye Institute Grand Rounds. Discussant William Culbertson. November 19, 2009

Driscoll, D, Yoo S. *SubTenons Ranibizumab for the Inhibition of Neovascularization in the Cornea in High Risk Corneal Transplant Surgery*. Bascom Palmer Residents Day 2009, Miami, Florida, June 19, 2009.

Driscoll, D. *Current pharmacologic treatment modalities for proliferative vitreoretinopathy with subfocus on methods of intravitreal sustainable drug delivery*. Retina morning conference. Bascom Palmer Eye Institute. April 22, 2009.

Driscoll, D. *Refractive screening and vision correction with ready-made glasses in Belize*. Bascom Palmer Eye Institute Grand Rounds. Discussant Tom Shane, MD. April 16, 2009.

Driscoll D, et. al. ASCRS April 3-8, 2009 San Francisco, CA: Poster presentation: *Allopatric Femtosecond Laser Air Bubble Formation in a Closed System*

Driscoll, D. ASCRS April 7, 2009 San Francisco, CA: Sports Ophthalmology Society of the Americas Guest Speaker: *Sports-Related Ophthalmic Injuries*

Driscoll, D. *Malignant meningioma case presentation*. Bascom Palmer Eye Institute Grand Rounds. Discussant Norman Schatz, MD. February 19, 2009.



Driscoll, D. *IOL calculations after PRK and Lasik Surgery*. Bascom Palmer Eye Institute morning lecture. January 5, 2009

Driscoll, D. *Unusual retinal vasculitis with complication of corneal perforation*. Bascom Palmer Eye Institute Grand Rounds. Discussants Thomas Albini, MD and Victor Perez, MD. December 4, 2008.

Driscoll D, Davis J. *A 19 year old female has transient black spots, headaches. Stellate maculopathy, disc edema occur during treatment: What is your diagnosis?* Ophthalmology Times 2008; Nov 15: 8-10.

Driscoll D, Karp, C. *Conjunctival Intraepithelial Neoplasia*. Southeast Cornea Conference, Asheville, North Carolina, September 19, 2008.

Driscoll, D. *Trauma Case Discussion: Nail to the Orbit*. OphthalmologyWeb.com featured article. September 2008.

<http://www.opthalmologyweb.com/FeaturedArticle.aspx?spid=23&aid=403&headerid=23>

Driscoll, D. *Neovascular Glaucoma: Emergency Treatment Experiences*. OphthalmologyWeb.com featured article. August 2008.

<http://www.opthalmologyweb.com/FeaturedArticle.aspx?spid=23&aid=399&headerid=23>

Driscoll, D. *Masquerading papillophlebitis in a healthy 19 year old female*. Bascom Palmer Eye Institute Grand Rounds. Discussant Janet Davis, MD. July 31, 2008.

Driscoll D, Yoo, S. *Pilot Study: Prevalence of Demodex folliculorum in the eyelashes of all comers*. Bascom Palmer Eye Institute Residents Day 2008, Miami, Florida, June 13, 2008.

Driscoll, D. *White retinal lesion in immunosuppressed pediatric patient with history of leukemia*. Bascom Palmer Eye Institute Grand Rounds. Discussant Janet Davis, MD. June 5, 2008.

Driscoll, D. *Differentiating severe keratitis from endophthalmitis: Management and diagnostic strategies*. Bascom Palmer Eye Institute Grand Rounds. Discussant Elena Roth, MD. March 20, 2008.

Driscoll, D. *Case report: Blindness due to fludarabine toxicity*. Bascom Palmer Eye Institute Grand Rounds. Discussant Norman Schatz, MD. November 15, 2007.

Driscoll, D. *Bilateral Herpes Simplex virus acute retinal necrosis*. Bascom Palmer Eye Institute Grand Rounds. Discussant Thomas Albini, MD. August 23, 2007

#### Ophthalmic Research

2009 - 2011      *The effect of resistance training on microsurgical tremor.*  
Collaboration of Bascom Palmer Eye Institute and University of Miami Medical Wellness Center.

2004 - 2005      The Effect of a Cataract Surgery Incision on Corneal Wavefront.  
OSUCOMPH Department of Ophthalmology, Columbus, Ohio.  
Thomas Mauger, M.D., Jennifer Lewis, Ph.D.

#### Past Research

2000 - 2002      CWRU Department of Biochemistry: Development of gene therapy techniques in yeast by inducing genomic damage and supplying exogenous nucleotide sequences in hopes of cellular incorporation and genotypic conversion.

#### Academic Achievements

2006      Eli G. Alcorn and John B. Alcorn Prize in Ophthalmology for outstanding achievement in ophthalmology.  
2006      Alpha Omega Alpha medical honor society  
2005      Orr scholarship in medicine, OSU  
2004      Helmick Scholarship, OSU

2004	OSU College of Medicine Student Service Award
2003	OSU Scholarship in Medicine
2002	Dean's High Honors
2002	Harland G. Wood Biochemistry Award, Case Western Reserve University
2001	Golden Key National Honor Society
1998	Case Western Reserve University Trustee's Scholarship

**Committees**

2006 - 2007	Mercy Hospital Transitional Year Curriculum Review Committee Resident Representative
2003 - 2004	Integrated Pathway Academic Programming Committee The Ohio State University College of Medicine and Public Health Student Representative

This certifies that

Jana Miki'ala Souza, OD

SAMPLE

has successfully attended and completed

INTERVENTIONAL GLAUCOMA ADVANCES/ISTENT AND


IDOSE

For 2 CE TPA Certification Credits

Course # 25-005

On July 25, 2024

March 5, 2025





Dan Driscoll, MD

presenting ophthalmologist

HAWAII VISION SPECIALISTS



State of Hawaii  
Department of Commerce and Consumer Affairs  
**HAWAII BOARD OF OPTOMETRY**  
335 Merchant St., 3rd Floor, Honolulu, HI 96813  
Mailing Address: P.O. Box 3469, Honolulu, HI 96801  
Access this form via website at: [cca.hawaii.gov/pvl](http://cca.hawaii.gov/pvl)

**PROGRAM SPONSOR AGREEMENT FOR CONTINUING EDUCATION ("CE")****PROGRAM TITLE:**Update on MIGS & interventional glaucoma**INSTRUCTIONS**

1. Submit this original completed application form for each course title no more than 45 days after the course is completed;
- ✓ 2. Attach a program outline including time schedule;
- ✓ 3. Attach course description;
- ✓ 4. Attach curriculum vitae of all lecturer(s);
- ✓ 5. Attach a copy of the certificate of attendance (please see Hawaii Administrative Rules §16-92-40(a) for the required information); and
6. Attach a check for \$25 made payable to: "COMMERCE & CONSUMER AFFAIRS". (check must be in U.S. dollars and be from a U.S. financial institution.)

**FOR OFFICE USE ONLY**

Index number 25-008  
Reviewed by Dr. P. Chir  
Approved by \_\_\_\_\_  
Amended date \_\_\_\_\_

SPONSOR'S NAME:

Jenkins Eye Care

PHONE NO.:

8085919911

EMAIL ADDRESS:

info@jenkinseyecare.com

TYPE OF ORGANIZATION:

private practice

BUSINESS ADDRESS:

615 Piikoi St. #205, Honolulu, HI 96814

LOCATION OF PROGRAM (City, State):

Honolulu, HI (virtual)

DATE OF PROGRAM:

2/11/2025


Total CE hour(s) being requested:

one

1 hours(s) will apply towards fulfilling the 36 hours of CE in the diagnosis, treatment and management of ocular and systemic diseases, required for license renewal of an optometrist with therapeutic pharmaceutical agent ("TPA") certification.

**The sponsor agrees that the program shall be such:**

1. That it will require and monitor the attendance;
2. That it will be at least 50 minutes in duration for each hour claimed from the beginning of the subject matter to its conclusion;
3. That it will be presented by a qualified lecturer, whose name, title, and qualifications are to be included in attached curriculum vitae;
4. That written records of its attendees and of the program outline shall be maintained in its files for a period of two years immediately following its conclusion;
5. That written evidence of attendance will be issued by the Sponsor to **each attendee** with the CE hour(s) and the Board's Hawaii Index Number shown thereon. The Board will not accept any certification of attendance or lists of attendees from the Sponsor. If any are received, they will be discarded;



(CONTINUED ON PAGE 2)

Print Name of Sponsor:

Jenkins Eye Care

Date:


2/3/2025

6. That the CE hour(s) requested are exclusive of any preparation time;
7. That the program records will be subject to review by the Hawaii Board of Optometry ("Hawaii Board") and the program sponsor agrees to make these records available to the Hawaii Board or its designee during regular business hours at the business address indicated on this application for a period of two years following the date of presentation; and
8. That the Hawaii Board will be notified as to the location of these records if they are removed from the above location prior to expiration of the above two year period.

In consideration for compliance with this agreement, we understand that we may advise prospective attendees of the approval of our program and the number of hours of credit allowable. If we fail to comply with this agreement or fail to meet acceptable standards in our program, we understand that approval of our program may be revoked by the Hawaii Board and that notice of such revocation may be given by the Hawaii Board to all licensees.

By

Signature of individual responsible for CE administration

2/3/2025

Date

Its

President, Ophthalmology

Title

Jeffrey R. Peterson, MD, PhD

Print name of individual responsible for CE administration

**(THIS FORM MAY BE DUPLICATED)**

Print Form



This material can be made available for individuals with special needs. Please call the Licensing Branch Manager at (808) 586-3000 to submit your request.

Course Title: Update on MIGS and Interventional Glaucoma

Program Outline:

7:00PM – 8:00PM VIA ZOOM – PRESENTATION BY DR. JEFFREY PETERSON

Course Description:

Dr. Jeff Peterson, who will provide an informative update on MIGS (Minimally Invasive Glaucoma Surgery) and interventional glaucoma. Discover the latest advancements and gain insights into when to recommend these treatments for your patients.





JENKINS EYE CARE

DATE: February 11, 2025

PLACE: Zoom Virtual Meeting

HOURS: 1.0 TPA (one) credit hours

COURSE: Updates in MIGS and Interventional Glaucoma

INSTRUCTORS: Jeffrey Peterson, MD, PhD

**This form verifies attendance at the above course (#25-\_\_\_\_)**


NAME OF ATTENDEE: \_\_\_\_\_

EDUCATION CHAIR: \_\_\_\_\_

  
Jeffrey Peterson, MD, PhD



**JEFFREY R. PETERSON, M.D., PH.D.**



*Handwritten signature*  
*Nov. 4, 2024*

#### CURRENT POSITION

Partner, Jenkins Eye Care, 615 Piikoi Street Suite 205, Honolulu, HI 96814  
 12/2015-present

#### EDUCATION

University of Texas Medical School at Houston, Robert Cizik Eye Clinic, Houston, TX  
 07/2014-07/2015  
 Clinical Fellow, Glaucoma

Baylor College of Medicine, Houston, TX  
 06/2011-06/2014  
 Resident, Ophthalmology

Saint Joseph Mercy Hospital, Ann Arbor, MI  
 06/2010-06/2011  
 Intern (PGY-I), Transitional Year Program

Weill Cornell/Rockefeller/Sloan-Kettering  
 Tri-Institutional MD-PhD program, New York, NY  
 06/2006-06/2010  
 Ph.D. awarded 10/2008  
 M.D. awarded 06/2010

University of Iowa Carver College of Medicine, Iowa City, IA  
 06/2003-07/2006  
 Medical Scientist Training Program  
 Transferred, 07/2006

University of California, Los Angeles  
 09/1999-06/2003  
 B.S., Neuroscience major, *cum laude*, 06/2003

Iolani High School, Honolulu, HI  
 08/1995-06/1999  
 Diploma, *cum laude*, 06/1999





## **INDEPENDENT FUNDING**

NIH/NINDS Ruth L. Kirschstein National Research Service Award for Individual  
Predoctoral MD/PhD Fellows, 2008-2010

## **AWARDS AND DISTINCTIONS**

Chief Resident, Baylor Ophthalmology, 2013-2014  
Caroline tum Suden/Frances Hellebrandt Professional Opportunity Award, 2008  
Cornell University Center for Vertebrate Genomics Travel Award, 2007  
Trainee Travel Fellowship for FASEB Summer Research Conference, 2007  
Merck New Investigator Award, 2006  
Alpha Omega Alpha (Junior), 2005  
Robert Roberts Award for Outstanding Performance in Medical Pharmacology, 2005  
Phi Beta Kappa, 2003  
Werner R. Scott Fellowship, 2001-2003  
Golden Key National Honor Society, 2001  
National Society of Collegiate Scholars, 1999

## **CLINICAL STUDIES**

Sub Investigator, Aerie Pharmaceuticals, CS205 Phase II study, 2018  
  
Principal Investigator, Allergan, XEN-45 Gel Stent Versus Trabeculectomy in Glaucoma: Gold-Standard  
Pathway Study, 2019

## **RESEARCH EXPERIENCE**

Cornell University:  
College of Veterinary Medicine, Department of Biomedical Sciences, &  
Weill Cornell Medical College, Department of Cell and Developmental Biology  
Graduate Student, 07/2006-10/2008  
Mentor: Robin L. Davisson, Ph.D.

University of Iowa, Department of Anatomy and Cell Biology  
Graduate Student, 07/2004-07/2006  
Mentor: Robin L. Davisson, Ph.D.

Laboratory of Neurophysiology, UCLA Neuropsychiatric Institute  
Laboratory Assistant, 10/2002 – 06/2003  
Mentor: Joaquin Fuster, M.D., Ph.D.

Laboratory of Neuro Imaging, UCLA  
Laboratory Assistant, 01/2001- 06/2003  
Mentor: Jennifer G. Levitt, M.D.

## PUBLICATIONS

**Peterson JR**, Anderson JW, Blieden LS, Chuang AZ, Feldman RM, Bell NP. Long-term Outcome of Argon Laser Peripheral Iridoplasty in the Management of Plateau Iris Syndrome Eyes, *J Glaucoma*. 2017 Sep;26(9):780-786.

Melese E, **Peterson JR**, Feldman RM, Baker LA, Bell NP, Chuang AZ, Blieden LS. Comparing Laser Peripheral Iridotomy to Cataract Extraction in Narrow Angle Eyes Using Anterior Segment Optical Coherence Tomography. *PLoS One*. 2016 Sep 8;11(9).

Matoba AY, **Peterson JR**, Wilhelmus KR. Dendritiform Keratopathy Associated with Exposure to Polyquarternium-1, a Common Ophthalmic Preservative. *Ophthalmology*. 2016 Mar 123(3):451-6.

**Peterson JR**, Blieden LS, Chuang AZ, Baker LA, Rigi M, Feldman RM, Bell NP. Establishing Age-Adjusted Reference Ranges for Iris-Related Parameters in Open Angle Eyes with Anterior Segment Optical Coherence Tomography. *PLoS One*. 2016 Jan 27;11(1).

Wang G, Sarkar P, **Peterson JR**, Anrather J, Pierce JP, Moore JM, Feng J, Zhou P, Milner TA, Pickel VM, Iadecola C, Davisson RL. COX-1-derived PGE2 and PGE2 type 1 receptors are vital for angiotensin II-induced formation of reactive oxygen species and Ca(2+) influx in the subfornical organ. *Am J Physiol Heart Circ Physiol*. 2013 Nov 15;305(10):H1451-61.

Capone C, Faraco G, **Peterson JR**, Coleman C, Anrather J, Milner TA, Pickel VM, Davisson RL, Iadecola C. Central cardiovascular circuits contribute to the neurovascular dysfunction in angiotensin II hypertension. *J Neurosci*. 2012 Apr;32:4878-86.

Cao X, **Peterson JR**, Wang G, Anrather J, Young CN, Guraju MR, Burmeister MA, Iadecola C, Davisson RL. Angiotensin II-dependent hypertension requires cyclooxygenase 1-derived prostaglandin E2 and EP1 receptor signaling in the subfornical organ of the brain. *Hypertension*. 2012 Apr;59:869-76.

Ehrlich JR, **Peterson J**, Parlitsis G, Kay KY, Kiss S, Radcliffe NM. Peripapillary choroidal thickness in glaucoma measured with optical coherence tomography. *Exp Eye Res*. 2011 Mar;92:189-94.

**Peterson JR**, Burmesiter MA, Tian X, Guraju MR, Stupinski JA, Sharma RV, Davisson RL. Genetic silencing of Nox2 and Nox4 reveals differential roles of these NADPH oxidase homologues in the vasopressor and dipsogenic effects of brain angiotensin-II. *Hypertension*. 2009 Oct;54:1106-14.

**Peterson JR**. Central Redox Signaling Mechanisms in Neurogenic Hypertension. *Dissertations Abstracts International*, AAT 3349390, September 2009.

**Peterson JR**, Infanger DW, Braga VA, Zhang Y, Sharma RV, Engelhardt JF, Davisson

RL. Longitudinal Non-invasive Monitoring of Transcription Factor Activation in Cardiovascular Regulatory Nuclei Using Bioluminescence Imaging. *Physiological Genomics*. 2008, Apr;33(2):292-9.

**Peterson JR**, Sharma RV, Davisson RL. Reactive Oxygen Species in the Neuropathogenesis of Hypertension. *Current Hypertension Reports*. 2006 Jun;8(3):232-241.

Blanton RE, Levitt JG, **Peterson JR**, Fadale D, Sporty ML, Lee M, To D, Mormino EC, Thompson PM, McCracken JT, Toga AW. Gender differences in the left inferior frontal gyrus in normal children. *Neuroimage*. 2004 Jun;22(2):626-36.

Ballmaier M, Toga AW, Blanton RE, Sowell ER, Lavretsky H, **Peterson J**, Pham D, Kumar A. Anterior cingulate, gyrus rectus, and orbitofrontal abnormalities in elderly depressed patients: an MRI-based parcellation of the prefrontal cortex. *Am J Psychiatry*. 2004 Jan;161(1):99-108.

#### BOOK CHAPTERS

**Peterson J**, Ahmed R, Foroozan R. Visual Loss, Monocular. *Neurological Differential Diagnosis: A Case-Based Approach*. Cambridge: Cambridge, University Press, 2014.

#### ORAL PRESENTATIONS

##### National & International Scientific Meetings:

Dendritiform Keratopathy Associated with PQ-1. Ocular Microbiology and Immunology Group Annual Meeting, New Orleans, LA, 2013

“COX-1-derived PGE<sub>2</sub> acting on its type 1 receptor mediates Ang-II-dependent neurogenic hypertension.” Experimental Biology, New Orleans, LA, 2009

“Reactive oxygen species mediate Ang-II-dependent activation of CaMKII in forebrain circumventricular organs.” Experimental Biology, San Diego, CA, 2008

“Differential Roles for Nox2- and Nox4-containing NAD(P)H oxidases in the physiologic responses to central angiotensin-II.” 61<sup>st</sup> Annual Fall Conference and Scientific Sessions of the Council for High Blood Pressure Research, Tucson, AZ, 2007

“Nox2- and Nox4-containing NAD(P)H oxidases are differentially involved in the physiologic responses to central angiotensin-II.” Invited Speaker at FASEB Summer Research Conference on Neural Mechanisms of Cardiovascular Regulation, Bondi Beach, Sydney, Australia, 2007

“Both Nox2- and Nox4-containing NAD(P)H oxidases are required for the full vasopressor effects of angiotensin-II in the central nervous system.” Outstanding Trainee

Neural Control Session, Experimental Biology, Washington D.C., 2007

Institutional Seminars:

“COX-1-derived PGE<sub>2</sub> acting on its type 1 receptor in the subfornical rgan is required for the development of hypertension during peripheral Ang-II infusion.” Weill  
Cornell/Rockefeller/Sloan-Kettering Tri-Institutional MD-PhD Annual Retreat, Long Island, NY, 2008

“Nox2 and Nox4 containing NADPH oxidases mediate Ang-II neurogenic hypertension.”  
Frontiers Science Club Department of Cell and Developmental Biology Seminar, Well  
Cornell Medical College, New York, NY 2008

“Differential roles for Nox2- and Nox4-containing NADPH oxidases in the physiologic responses to central angiotensin-II.” Cornell University College of Veterinary Medicine  
Department of Biomedical Sciences Work in Progress Seminar, Ithaca, NY, 2007

“A role for Nox2-containing NAD(P)H oxidase in the physiologic responses to central angiotensin-II.” Weill Cornell/Rockefeller/Sloan-Kettering Tri-Institutional MD-PhD  
Annual Retreat, Long Island, NY, 2006

“Nox2-containing NADPH oxidase is required for the physiologic responses to central Ang-II”. University of Iowa Department of Anatomy and Cell Biology Seminar. Iowa  
City, IA, 2005

“A Possible Role for Redox-Regulated AP-1 Activation in the Neuropathogenesis of Angiotensin II-Induced Hypertension.” University of Iowa Carver College of Medicine  
Medical Student Research Day, Iowa City, IA, 2004

**POSTER PRESENTATIONS & ABSTRACTS**

**Peterson J.** Chuang A, Bell N, Rigi M, Nguyen D, Blieden L, Feldman R. “Iris parameters in open angle eyes measured with swept source Fourier domain anterior segment optical coherence tomography.” The American Glaucoma Society Annual Meeting 2015, San Diego, CA.

**Peterson J.** Foroozan R. “Characteristics of Ocular and Extra-Ocular Symptoms in Patients with Myasthenia Gravis Presenting with Isolated Ptosis.” The Association for Research in Vision and Ophthalmology Annual Meeting 2014, Orlando, FL.

**Peterson J,** Yen M, Foroozan R. “Distinctive Clinical Signs Differentiating Oculopharyngeal Muscular Dystrophy from Myasthenia Gravis”. The Association for Research in Vision and Ophthalmology Annual Meeting, Seattle, WA, 2013

**Peterson J,** Shimmyo M, Shammas M, Radcliffe N. “Corneal Biomechanical Analysis in

Glaucoma Screening". Poster presentation, Meeting of American Academy of Ophthalmology, San Francisco, CA, 2009

**Peterson JR**, Wang G, Burmeister M, Sharma RV, Anrather J, Iadecola C, Davisson RL. "COX-1-derived PGE<sub>2</sub> acting on its type 1 receptor mediates Ang-II-dependent neurogenic hypertension." Experimental Biology, New Orleans, LA, 2009

**Peterson JR**, Burmeister M, Sharma RV, Davisson RL. "Both Nox2- and Nox4-containing NADPH oxidases in the subfornical organ contribute to the hypertension evoked by slow-pressor Ang-II infusion." 62<sup>nd</sup> Annual Fall Conference and Scientific Sessions of the Council for High Blood Pressure Research, Atlanta, GA, 2008

**Peterson JR**, Burmeister M, Tian X, Stupinski J, Sharma RV, Davisson RL. "Both Nox2- and Nox4-containing NAD(P)H oxidases are required for the full vasopressor effects of angiotensin-II in the central nervous system." Experimental Biology, Washington D.C., 2007

DW Infanger, **JR Peterson**, RV Sharma, and RL Davisson. "Long-term in vivo monitoring of transcription factor activation in cardiovascular control regions of mouse brain using bioluminescence imaging." Experimental Biology, Washington D.C., 2007


**Peterson JR**, Kutschke W, Tian X, Sharma RV, Davisson RL. "Adenoviral-mediated silencing of Nox2 expression in forebrain circumventricular organs blunts the cardiovascular and dipsogenic responses to central angiotensin-II." 60<sup>th</sup> Annual Fall Conference and Scientific Sessions of the Council for High Blood Pressure Research, San Antonio, TX, 2006

**JR Peterson**, DW Infanger, W Kutschke, RV Sharma, & RL Davisson. "Viral gene transfer combined with bioluminescence imaging (BLI) for longitudinal monitoring of gene expression in targeted brain regions of mice." Experimental Biology, San Francisco, CA, 2006

**Jeffrey Peterson**, Francois M. Abboud, Mark W. Chapleau. "Developing a method for the quantification of atherosclerotic lesions in young ApoE<sup>-/-</sup> mice." University of Iowa Medical Scientist Training Program Annual Retreat, Iowa City, IA, August 2004

JG Levitt, R Blanton, **J Peterson**, R Woods, P Thompson, T Sadoun, C Kitchen, JT McCracken, A Toga. "3-Dimensional Brain Mapping in High-Functioning Autism." 58<sup>th</sup> Annual Society of Biological Psychiatry Meeting, San Francisco, CA, 2003





State of Hawaii  
 Department of Commerce and Consumer Affairs  
**HAWAII BOARD OF OPTOMETRY**  
 335 Merchant St., 3rd Floor, Honolulu, HI 96813  
 Mailing Address: P.O. Box 3469, Honolulu, HI 96801  
 Access this form via website at: [cca.hawaii.gov/pvl](http://cca.hawaii.gov/pvl)

**PROGRAM SPONSOR AGREEMENT FOR CONTINUING EDUCATION ("CE")**

**PROGRAM TITLE:** Adjustable IOLs: Reshaping the Refractive Surgery Land:

**INSTRUCTIONS**

1. Submit this original completed application form for each course title no more than 45 days after the course is completed;
- ✓ 2. Attach a program outline including time schedule;
- ✓ 3. Attach course description;
- ✓ 4. Attach curriculum vitae of all lecturer(s);
- ✓ 5. Attach a copy of the certificate of attendance (please see Hawaii Administrative Rules §16-92-40(a) for the required information); and
6. Attach a check for \$25 made payable to: "COMMERCE & CONSUMER AFFAIRS". (check must be in U.S. dollars and be from a U.S. financial institution.)

**FOR OFFICE USE ONLY**

Index number


25-009

Reviewed by

P. Chin

Approved by

Amended date



**SPONSOR'S NAME:** Jenkins Eye Care

**PHONE NO.:** 808-591-9911

**EMAIL ADDRESS:** pam@jenkinseyecare.com

**TYPE OF ORGANIZATION:** Private Practice

**BUSINESS ADDRESS:** 615 Piikoi Street, Suite 205, Honolulu, HI 96814

**LOCATION OF PROGRAM (City, State):** Honolulu, Hawaii via Zoom

**DATE OF PROGRAM:** 3/27/2025

**Total CE hour(s) being requested:** 1 (one)

1 hours(s) will apply towards fulfilling the 36 hours of CE in the diagnosis, treatment and management of ocular and systemic diseases, required for license renewal of an optometrist with therapeutic pharmaceutical agent ("TPA") certification.

**The sponsor agrees that the program shall be such:**

1. That it will require and monitor the attendance;
2. That it will be at least 50 minutes in duration for each hour claimed from the beginning of the subject matter to its conclusion;
3. That it will be presented by a qualified lecturer, whose name, title, and qualifications are to be included in attached curriculum vitae;
4. That written records of its attendees and of the program outline shall be maintained in its files for a period of two years immediately following its conclusion;
5. That written evidence of attendance will be issued by the Sponsor to **each attendee** with the CE hour(s) and the Board's Hawaii Index Number shown thereon. The Board will not accept any certification of attendance or lists of attendees from the Sponsor. If any are received, they will be discarded;

(CONTINUED ON PAGE 2)

Print Name of Sponsor:

Jenkins Eye Care

Date:

25-009  
2/3/2025

6. That the CE hour(s) requested are exclusive of any preparation time;
7. That the program records will be subject to review by the Hawaii Board of Optometry ("Hawaii Board") and the program sponsor agrees to make these records available to the Hawaii Board or its designee during regular business hours at the business address indicated on this application for a period of two years following the date of presentation; and
8. That the Hawaii Board will be notified as to the location of these records if they are removed from the above location prior to expiration of the above two year period.

In consideration for compliance with this agreement, we understand that we may advise prospective attendees of the approval of our program and the number of hours of credit allowable. If we fail to comply with this agreement or fail to meet acceptable standards in our program, we understand that approval of our program may be revoked by the Hawaii Board and that notice of such revocation may be given by the Hawaii Board to all licensees.

By

Signature of individual responsible for CE administration

Its


Title

Jeffrey R. Peterson, MD, PhD  
Print name of individual responsible for CE administration

Date

(THIS FORM MAY BE DUPLICATED)

Print Form



This material can be made available for individuals with special needs. Please call the Licensing Branch Manager at (808) 586-3000 to submit your request.




Course Timeline: 5:30p - 6:30p via zoom  
 Course Description:

Adjustable IOLs: Reshaping the Refractive Surgery Landscape  
 Nicholas J. Bruns, OD, FAA

Cataract surgery has changed dramatically over the past two decades. New surgical techniques and IOL options aim to provide a level of spectacle independence for patients once unheard of. The variability of each patient's healing process, as well as inaccuracies with modern IOL calculation formulas often result in refractive error. Adjustable IOLs, first introduced in 2019, are the latest breakthrough in cataract surgery that allow for an unprecedented level of refractive accuracy.

#### Objectives:

1. Attendees will better understand cataract surgery basics, including the barriers for refractive accuracy
  2. Attendees will become familiar for pros/cons of adjustable IOLs. Discussion will highlight several technologies, including those in the pipeline
  3. Attendees will increase comfort in managing patients electing an adjustment IOL, both pre and postoperatively.
- Cataract surgery
    - Barriers to overcome to achieve refractive accuracy
      - Effective lens position - where the IOL will sit exactly with relation to the cornea and retina
      - Modern IOL formulas
        - Barrett, Barrett TK toric, Holladay II, etc
      - Corneal irregularity
        - Post-LASIK cases - why are these notoriously difficult for cataract surgeons?
          - Example: 25 D IOL ends up 1 mm anterior of where it should be
            - ~7% of IOL power for every mm of deviation.
            - $0.07 \times 25 = 1.75$  D. IOL is roughly  $\frac{2}{3}$  of power at corneal plane, therefore we end with a 1.16 D refractive miss
      - Dry Eye - potential influence
        - Biometry
        - Astigmatism
        - Postoperative visual fluctuation
    - Axial length
    - Patient expectations - the psychology of today's patient
      - Expectations are much higher than ever before
      - Early LASIK patients are now cataract patients
- Traditional vs Adjustable
  - Traditional method: Prediction based decision





- Preop biometry drives IOL selection. Cannot take into account variability in healing process
  - "Fit patient to the lens"
- Adjustable IOL method: Trial based decision
  - Preop biometry, while still important, not as crucial
  - "Fit lens to the patient"
  - Most patients elect for a certain level of monovision. The degree of tolerable anisometropia is highly variable, and is much better tolerated with adjustable lenses.
  - Astigmatism - ability to add toricity postoperatively, up to 2 DC
    - Eliminates risk of rotation (~3% incidence rate with traditional toric IOLs)
- How does the adjustable lens work
  - UV activated macromers suspended in silicon matrix. Macromers bind when exposed to UV light, ultimately changing the shape of lens to match desired refractive outcome
- New Adjustable Lens (Light Adjustable Lens+): commercially available as of January 2024
  - Added asphericity for improved reading; less DVA compromise ⇒ retained stereopsis
- Who's a good candidate?
  - Various premium IOLs are contraindicated in patients with retinal or corneal disease
    - Optics of Multifocal/EDOF IOLs: Splitting light into multiple focal points induces higher order aberrations
    - Adjustable IOL - monofocal with aspheric design
      - Less higher order aberrations than MF/EDOF IOL, therefore can be considered in patients with pathology
- The Optometrists' role
  - Adjustment Process:
    - First light adjustment at least 17 days post op
    - Adjustments at least 3 days apart (more time between adjustments is recommended). Optional 3 adjustments with 2 mandatory lock-ins.
      - Similar to contact lens fit - patient "test drives" refractive target before making final decision
  - Optometrists are able to provide refractive precision and an added element of quality control. Process is an art - need to be able to communicate effectively with patients.
  - Refractive targeting strategies
    - "Blended Vision" - not true monovision. More tolerable anisometropia = retained binocularity
    - Optional added negative spherical aberration to further enhance depth of focus in non-dominant eye
  - Refraction tips

- Maintenance therapy during treatments - UV light increases dry eye symptoms
  - PF AT's QID at minimum
- Light adjustments are UV light, NOT Laser. No tissue is being manipulated = In scope in most US states
- Conclusion



JENKINS EYE CARE

DATE: March 27, 2025

PLACE: Zoom Virtual Meeting

HOURS: 1.0 TPA (one) credit hours

COURSE: Adjustable IOLs: Reshaping the Surgical Landscape"

INSTRUCTORS: Nick Bruns, OD, FAAO

**This form verifies attendance at the above course (#25-\_\_\_\_)**

NAME OF ATTENDEE: \_\_\_\_\_

EDUCATION CHAIR: \_\_\_\_\_

  
Jeffrey Peterson, MD, PhD

# Nicholas J. Bruns, O.D., F.A.A.O.

## Education

**Michigan College of Optometry at Ferris State University** 2011-2015  
 Big Rapids, MI  
 Doctorate of Optometry – High Academic Honors

### Academic Honors:

MCO Senior Project Award in Pediatrics	2015
Beta Kappa Sigma Honor's Society	2014-2015
Dean's List	2011-2014
Travel Grant Winner - Vision Expo East	2013
Midland Lions Club Scholarship	2013
Bernard F. and Mellissa Anne Bailey Memorial Scholarship	2013
Walman Optical Company Scholarship	2013
Awarded Early Admittance	2011
Received Weeks-Lakin Scholarship upon admission	2011

**Central Michigan University** 2007-2011  
 Mt. Pleasant, MI  
 Bachelor's of Science in Biomedical Sciences - Cum Laude

### Academic Honors:

Olive Hutchinson Kries Memorial Scholarship	2011
Central Michigan Honors Program	2007-2011
Dean's List	2007-2009, 2011
President's List	2010

## Professional Experience

**Summit Eye Care of Wisconsin** January 2020 - Present  
 Milwaukee, WI  
 Senior Optometrist, Director of Practice Development

- Clinical duties
  - Lead for integration of Light Adjustable Lens technology
  - Education and certification of co-managing referral base
  - Pre/post-operative care: Cataracts with emphasis on premium IOLs, ICL, MIGS, and in-office procedures
  - Glaucoma, Ocular Disease
- Lead role in developing new Milwaukee clinic (opened in January 2020)
- Director of practice co-management program - developed and maintained relationships with referring physicians

Nicholas J. Bruns  
Nicholas.j.bruns@gmail.com

---

- Education Director
  - Organized semi-annual education events for local optometrists
  - Coordinated optometric internship program

**Gondola Eye / Praxis** January 2020 - Present  
Minneapolis, MN  
Corporate Optometric Consultant

- Assisted with development strategy of model centered around light adjustable lens
- Participated in development of marketing strategies

**Michigan College of Optometry**

Clinical Adjunct Assistant Professor Summer 2023 - Present

- Director of student intern program at Summit Eye Care of WI

**Peer to Peer Academy**

President July 2024 - Present

- Online educational platform partnering with industry highlighting new technology in anterior segment and refractive surgery
- Website: [Peertopeer.academy](https://Peertopeer.academy)

**Consultative / KOL Roles:**

**RxSight**  
Consultant, Speaker 2020 - Present

**STAAR Surgical**  
Consultant, Speaker 2021 - Present

**Glaukos**  
Speaker, Consultant 2022 - Present

**Bausch & Lomb Pharmaceuticals**  
Speaker 2024 - Present

**LENSAR**  
Consultant, Speaker 2024 - Present

**iDoc Social**  
Content creator, consultant 2024 - Present

**Abbvie**  
Consultant 2024 - Present

**Nordic Pharmaceuticals**  
Consultant 2024-Present

**Michigan Eye Institute** June 2015 – December 2019  
Flint / Grand Blanc, MI  
Associate Optometrist



Nicholas J. Bruns  
Nicholas.j.bruns@gmail.com

---

**Special Interest: Glaucoma, Pre/Post-operative care**

- Provided primary care services in a medical setting while working directly alongside ophthalmologists of different subspecialties
- Worked directly under fellowship-trained glaucoma specialist managing surgical and non-surgical cases. Became familiar with various filtration procedures as well as MIGS and laser based treatments.
- Pre/post-op management of refractive procedures
- Director of contact lens services

**Fourth Year Optometry School Rotations:**

<b>Great Lakes Eye Institute</b>	Summer 2014
Saginaw, MI	
Pre/Post-op, Ocular disease, Primary Care, Contact Lenses	
<b>Kresge Eye Institute</b>	Fall 2014
Detroit, MI	
Primary Care, Pediatrics, Low Vision, Contact Lenses	
<b>Grand Rapids VA Hospital</b>	Spring 2014
Grand Rapids, MI	
Primary Care, Ocular Disease	

<b>Michigan College of Optometry</b>	2012- 2014
Big Rapids, MI	
Student Intern- Primary Care, Contact Lens, Pediatrics/ Vision Therapy	
<b>Baldwin Health Clinic</b>	Fall 2013
Baldwin, MI	
Student Intern- Primary Care, Pediatrics	
<b>Great Lakes Eye Institute</b>	Summer 2013
Saginaw, MI	
Optometric Technician	
<b>Mid-Michigan Medical Center</b>	2009-2011
Midland, MI	
Student Intern- Invasive Imaging Department	

<b>Professional Organizations</b>
-----------------------------------

Intrepid Eye Society	2024 - Present
American Academy of Optometry	2022 - Present
Fellow (completed October 2022)	
Wisconsin Optometric Association	2020 - Present
Education Committee	
Milwaukee Optometric Society	2020 - Present
Treasurer	

Nicholas J. Bruns  
Nicholas.j.bruns@gmail.com

American Optometric Association	2015 - Present
National Glaucoma Society	2018 - Present
Eye Tea - Podcast	2022
Core team member, season two	
Director, Optometry	
Michigan Optometric Association	2015 - 2019
Saginaw Valley Optometric Society	2015 - 2019

### Articles / publications

- "Cataract vs Refractive Surgery: What's the Difference?". Modern Optometry. **August 2024**
- "Adjustability Reimagined". Presbyopia Physician. **June 2024**
- "What's New in Dry Eye Management?". Modern Optometry. **March 2024**
- "Using the IC-8 Aphthera IOL". Presbyopia Physician. **March 2024**
- "EVO ICL: A Game Changer in Refractive Surgery". Presbyopia Physician. **December 2023**
- "Considerations in Co Management of Glaucoma". Podcast. Ophthalmology 360. **July 2023**
- "Break the Barriers to Corneal Collagen Crosslinking". Optometric Management. **May 2023**
- "The Light Adjustable Lens: Reshaping the Premium IOL Landscape". Presbyopia Physician. **March 2023**
- Bloomenstein M, Bruns N, Ondhia A. "Advancing Refractive Surgery". Review of Optometry. **January 2023**
- Bruns N, Vukich J. "Correcting High Myopia at the Nodal Point". Modern Optometry. **October 2022**
- Vukich J, Bruns, N. "EVO ICL: Long-Lasting Quality of Vision". The Ophthalmologist. **August 2022**

### Presentations / Lectures / Seminars

- STAAR Surgical - OD Summit **December 2024**  
Panelist: Let's Talk about Vault  
Seeking out the Ideal Patient  
Talking all things EVO
- Glaucoma Grand Rounds **November 2024**  
Summit Eye Care Clinical Challenges Day
- The Integrated Care Model - Panelist **November 2024**  
STAAR Surgical - Surgeons Summit
- Academy of Optometry - Annual Meeting **November 2024**  
"Migs: Lasers and Blebs and Stents, Oh My!" - 2 hour COPE approved  
"Pupillary Block in an ICL patient" - Ellerbrock Grand Rounds

- 
- Wisconsin Optometric Association, Northwoods Retreat **October 2024**  
2 hour - COPE approved  
Modern Cataract Surgery With a Side of Glaucoma
  - MODLive - Nashville, TN **September 2024**  
So you want to work with industry? - Panel member  
The Pressure is on: All things glaucoma - Panel member  
Light Adjustable Lens - Breakout session leader
  - Minnesota Optometric Association Fall Meeting **September 2024**  
3 hours - COPE approved:
    - "Perioperative Management 101"
    - "Adjustable Lenses: Reshaping the Surgical Landscape"
    - "Phakic IOLs: The Old and the New"
  - LENSAR Referring OD webinar **July 2024**  
Webinar - Panelist
  - The Changing Premium IOL Landscape **June 2024**  
Lecture - AOA Optometry's Meeting
  - Light Adjustable Lens - Livestream. Ophthalmology Management **May 2024**  
Webinar
  - Light Adjustable Lens - Dinner Program **May 2024**  
Lecture sponsored by Salient Medical - Windsor, ON
  - "Refractive Surgery Showdown: Lasers vs Lenses" **April 2024**  
Lecture - Summit Eye Care Clinical Challenges Day
  - "Femtosecond Laser Assisted Cataract Surgery" **April 2024**  
Lecture - Summit Eye Care Clinical Challenges Day
  - RxInsight - "Challenging Cases" **March 2024**  
OD Webinar Series - host
  - "EVO ICL Pre and Post Op Considerations" - Lecture **January 2024**  
EVO ICL Practice Champions Meeting - Dallas, TX
  - "Moderated Takeaways and Opportunities" - Panel Discussion **January 2024**  
EVO ICL Practice Champions Meeting - Dallas, TX
  - RxInsights - "Light Adjustable Lens - Clinically your patient is great, but they're still unhappy... now what?" **November 2023**  
OD Webinar Series - host
  - "Managing the Premium IOL Patient" **October 2023**  
1-Hour Lecture, Co-presenter - COPE approved  
Academy of Optometry - Annual Meeting
  - "Beyond Traditional IOLs: The Light Adjustable Lens" **September 2023**  
Lecture / workshop - MODLive 2023, Nashville, TN
  - "The Light Adjustable Lens" **August 2023**  
1-hour lecture - Milwaukee Optometric Society
  - "EVO ICL" **August 2023**  
1-hour Lecture - Silk Vision and Surgical Center - Annandale, VA
  - "OD Referral Guide" **June 2023**  
1-hour lecture - Summit Eye Care Clinical Challenges Day

Nicholas J. Bruns  
Nicholas.j.bruns@gmail.com

- 
- Anterior Segment Grand Rounds **June 2023**  
Summit Eye Care Clinical Challenges Day: Panel Discussion
  - Posterior Segment Grand Rounds **June 2023**  
Summit Eye Care Clinical Challenges Day: Panel Discussion
  - RxInsights - "Light Adjustable Lens, Maximizing outcomes"  
OD Webinar series - Host **June 2023**
  - RxInsights - "Light Adjustable Lens, OD strategies"  
OD Webinar series - Host **March 2023**
  - Phakic IOL's: The Old and the New" **November 2022**  
1-Hour Lecture -Summit Eye Care Clinical Challenges Day
  - Light Adjustable Lens Roundtable Series: The OD perspective  
Panel member **September 2022**
  - Wisconsin Optometric Association - Primary Care Symposium  
Co-chair **2021, 2022**
  - "Perioperative Management 101"  
1-hour Lecture - Summit Eye Care Clinical Challenges Day **January 2022**
  - "Clinical Challenges and Alternative Approaches"  
Summit Eye Care Clinical Challenges Day: Panel Discussion **January 2022**
  - "Shining Light on a New Era in Collaborative Cataract Management"  
Sponsored presentation at Academy of Optometry (Boston, MA):  
Co-Presenter **November 2021**
  - "Diagnosis, Treatment & Management of the Keratoconus Patient"  
Wisconsin Valley Optometric Society: 1 Hour Lecture **October 2021**
  - "Minimally Invasive Glaucoma Surgery"  
1-Hour Lecture, Co-presenter - Summit Eye Care Clinical Challenges Day **June 2021**
  - Light Adjustable Lens **April 2021**  
Minneapolis, MN - Panel discussion
  - Glaucoma and Keratoconus **June 2020**  
Webinar - 2 hours  
Discussion leader, contributing presenter
  - "Light Adjustable Lens - Reshaping the IOL Market" **January 2020**  
1 hour lecture - Co-Presenter
  - "Retinal Venous Occlusive Disease and Associated Cardiovascular Risk"  
Case Presentation **May 2018**  
Michigan State University Flint Area Medical Education Conference
  - "Contact Lens Acute Red Eye"  
Case Presentation **November 2013**  
Michigan College of Optometry at Ferris State University

#### **Advisory Boards**

- Bausch and Lomb Pharmaceuticals - Academy of Optometry **November 2024**
- Nordic pharmaceuticals - Academy of Optometry **November 2024**
- Glaukos Cornea - Vision Expo West **September 2024**

Nicholas J. Bruns  
Nicholas.j.bruns@gmail.com

### Miscellaneous

- Young OD Mentor Session **December 2024**  
Bryn Mawr Communications
- Innovations in Vision and Eye Care **November 2024**  
Academy of Optometry - Showcase presenter

### Clinical Trials, Research

- Clinical Outcomes of Patients Bilaterally Implanted with the Commercially Available RxSight Light Adjustable Lens+ (LAL+) - PMCS-009  
Co-investigator **Fall 2023 - Winter 2024**
- Clinical Outcomes of Patients Bilaterally Implanted with the Commercially Available RxSight Light Adjustable Lens+ (LAL+) - PMCS-007  
Co-investigator **Summer-Fall 2023**
- Clinical Outcomes of Patients Bilaterally Implanted with the Commercially Available RxSight Light Adjustable Lens (LAL) - PMCS-006  
Co-investigator **Summer-Fall 2023**
- Clinical Outcomes of Patients Implanted with the Commercially Available RxSight Light Adjustable Lens (LAL) - PMCS-001  
Co-investigator **Fall 2022**
- Clinical Outcomes of Patients Bilaterally Implanted with the Commercially Available RxSight Light Adjustable Lens (LAL) - PMCS-002  
Sub-Investigator **Spring 2022**
- "Effects of Blur on Grooved Pegboard"  
Main Author **August 2014**  
Michigan College of Optometry at Ferris State University
- "Gender effects of cytochrome oxidase in a 5xFAD mouse model"  
Main Author **2010-2011**  
Central Michigan University
- "Early behavioral assessment in the 5xFAD model of Alzheimer's Disease"  
Assistant Author **2010-2011**  
Central Michigan University

### Extra-Curricular Activities

- |  |           |
|--|-----------|
| Hartland High School Football – Assistant Coach          | 2018-2019 |
| MCO chapter of Beta Sigma Kappa Honor's Society          | 2013-2014 |
| MCO Student Government                                   | 2011-2014 |
| Michigan Optometric Student Private Practice Association | 2011-2014 |



Nicholas J. Bruns  
Nicholas.j.bruns@gmail.com

---

American Optometric Student Association	2011-2014
MCO Student Ambassador for Admissions	2011-2013
Central Michigan University Pre-Optometry Club	2007-2011
President:	2011
Vice President:	2010
Social Chair:	2009
Central Michigan University Club Baseball Team	2008-2011
Fundraising Chair:	2011
Lunch Buddies Mentor Program	2011
Big Brothers/ Big Sisters Mentor Program	2008-2009

**PROGRAM SPONSOR AGREEMENT FOR CONTINUING EDUCATION ("CE")**

**PROGRAM TITLE:** Hawaii Optometric Association Live Virtual CE

**INSTRUCTIONS**

1. Submit this original completed application form for each course title no more than 45 days after the course is completed;
2. Attach a program outline including time schedule;
3. Attach course description;
4. Attach curriculum vitae of all lecturer(s);
5. Attach a copy of the certificate of attendance (please see Hawaii Administrative Rules §16-92-40(a) for the required information); and
6. Attach a check for \$25 made payable to: "COMMERCE & CONSUMER AFFAIRS". (check must be in U.S. dollars and be from a U.S. financial institution.)

FOR OFFICE USE ONLY	
Index number	<u>25-010</u>
Reviewed by	<u>P. Chin</u>
Approved by	_____
Amended date	_____

**SPONSOR'S NAME:** Hawaii Optometric Association

**PHONE NO.:** 808-537-5678

**EMAIL ADDRESS:** hoapt@earthlink.net

**TYPE OF ORGANIZATION:** Professional Association

**BUSINESS ADDRESS:** 98-820 Moanalua Rd., #15-1/179; Aiea, Hawaii 96701

**LOCATION OF PROGRAM (City, State):** Honolulu, Hawaii

**DATE OF PROGRAM:** April 27, 2025

**Total CE hour(s) being requested:** 4

4 hours(s) will apply towards fulfilling the 36 hours of CE in the diagnosis, treatment and management of ocular and systemic diseases, required for license renewal of an optometrist with therapeutic pharmaceutical agent ("TPA") certification.

**The sponsor agrees that the program shall be such:**

1. That it will require and monitor the attendance;
2. That it will be at least 50 minutes in duration for each hour claimed from the beginning of the subject matter to its conclusion;
3. That it will be presented by a qualified lecturer, whose name, title, and qualifications are to be included in attached curriculum vitae;
4. That written records of its attendees and of the program outline shall be maintained in its files for a period of two years immediately following its conclusion;
5. That written evidence of attendance will be issued by the Sponsor to **each attendee** with the CE hour(s) and the Board's Hawaii Index Number shown thereon. The Board will not accept any certification of attendance or lists of attendees from the Sponsor. If any are received, they will be discarded;

(CONTINUED ON PAGE 2)

Print Name of Sponsor: Hawaii Optometric AssociationDate: April 1, 2025

6. That the CE hour(s) requested are exclusive of any preparation time;
7. That the program records will be subject to review by the Hawaii Board of Optometry ("Hawaii Board") and the program sponsor agrees to make these records available to the Hawaii Board or its designee during regular business hours at the business address indicated on this application for a period of two years following the date of presentation; and
8. That the Hawaii Board will be notified as to the location of these records if they are removed from the above location prior to expiration of the above two-year period.

In consideration for compliance with this agreement, we understand that we may advise prospective attendees of the approval of our program and the number of hours of credit allowable. If we fail to comply with this agreement or fail to meet acceptable standards in our program, we understand that approval of our program may be revoked by the Hawaii Board and that notice of such revocation may be given by the Hawaii Board to all licensees.

By Charlotte Nekota  
Signature of individual responsible for CE administration

April 1, 2025

Date

Its Executive Director

Title

Charlotte Nekota

---

 Print name of individual responsible for CE administration

(THIS FORM MAY BE DUPLICATED)

Print Form



This material can be made available for individuals with special needs. Please call the Licensing Branch Manager at (808) 586-3000 to submit your request.



**Please join us for our live virtual event for 4 hours of TPA continuing education credits via ZOOM**

Date: Sunday, April 27, 2025 9:00 am – 1:00 pm


**Speakers**

Dr. Mark Sawamura

Pituitary Adenoma and Anterior Visual Pathway Tumors

Dr. Judy Tong

Evidence Based Management of Glaucoma



Cost: HOA Members \$50 Non-Members: \$150

Please make check payable to: Hawaii Optometric Association

Mail to: Hawaii Optometric Association

98-820 Moanalua Rd., Unit 15-1/179

Aiea, HI 96701

Ph: (808) 537-5678 Fax: (808) 537-1509 E-Mail: hoaopt@earthlink.net

**\*\*A link to the seminar will be emailed to you\*\***

**\*\*Please RSVP by April 22, 2025\*\***

Registration information: Please submit with your Payment

Name: \_\_\_\_\_ HOA Member \_\_\_\_\_

Mailing Address: \_\_\_\_\_

Email: \_\_\_\_\_ Phone: \_\_\_\_\_

If you would like to pay with a credit card, please call Charlotte Nekota at (808) 537-5678

April 27, 2025

Dr. Mark Sawamura is currently an Associate Professor with Tenure at the Southern California College of Optometry. He is a 1991 graduate of the Southern California College of Optometry and returned to teach at his alma mater following a post-graduate residency at the Pennsylvania College of Optometry / Hahnemann University. He joined the faculty of the Southern California College of Optometry in 1993.

Dr. Sawamura serves as the Chief of the Jarnagin Center for Primary Eye Care and Chief of Ocular Disease at the University Eye Center at Ketchum Health as well as attending faculty in the Special Testing Service. He teaches the neuro-ophthalmic disease track at the College as well as advanced ophthalmic procedures, application of lasers in ophthalmic practice and ocular disease courses. He has presented multiple lectures up to the national level in the area of ocular disease management and has been involved in many therapeutics courses for California, Hawaii, and Washington.

Dr. Sawamura currently is a Fellow of the American Academy of Optometry, Oral Examination Chair for the Diplomate in Neuro-ophthalmic Disease, Webmaster for the Disease Section of the AAO, Committee member of the National Board of Examiners in Optometry, Past Chairman of the ASCO SIG on Optometric Informatics, and has authored TPA guides for California Optometrists. He authors medical abstracts for the Optometry Journal and was recently President of the Faculty Council at SCCO.






Dr. Mark Sawamura

Pituitary Adenoma is most commonly associated with bi-temporal hemianopsia. However, the clinical recognition of this entity can be more complex and easily missed by both physicians and optometrists. This presentation will discuss the incidence, etiology, clinical signs and symptoms as well as physical changes that patients may experience who harbor variants of pituitary adenoma.

**Dr. Judy Tong is an Associate Professor of Optometry and Assistant Dean of Residencies at the Southern California College of Optometry of the Marshall B. Ketchum University. She received her B.S. degree in Genetics from the University of California, Berkeley and her O.D. degree from the Southern California College of Optometry. She completed a one year residency in Primary Care Optometry at the Eye Institute of the Pennsylvania College of Optometry (Salus University). As the Assistant Dean of Residencies since November 2003, Dr. Tong serves to provide global administrative and educational direction to 24 residency programs across 6 different states. Her main academic responsibility is teaching anterior segment diseases, basic and advanced procedures including lasers, injection, and suturing. Dr. Tong is one of the core instructors of the glaucoma certification courses and grand rounds program in California. Dr. Tong's research activities include being the Principal Investigator and Co-Investigator on two phase III antibiotic drug trials and major allergy study.**

Dr. Judy Tong

This course will cover first review current treatment options of glaucoma including topical drug therapy, surgical intervention and alternate drug delivery systems. Ocular surface disease as it relates to glaucoma treatment. Then there will be an analysis of pivotal glaucoma studies and how the new findings may shift the current treatment paradigm



# HAWAII OPTOMETRIC ASSOCIATION

DATE 4/27/2025 PLACE Honolulu HOURS 4

COURSE NAME Hawaii Optometric Association Live Virtual CE

INSTRUCTOR Drs. Judy Tong; Dr. Mark Sawamura

This form, properly signed by the H.O.A. Education Chairman and an Education Session Assistant verifies attendance at the above course by:

(NAME OF ATTENDEE) \_\_\_\_\_

Attest Education Assistant \_\_\_\_\_

Education Chairman \_\_\_\_\_

(Submit with license renewal)

State of Hawaii  
Department of Commerce and Consumer Affairs  
**HAWAII BOARD OF OPTOMETRY**  
335 Merchant St., 3rd Floor, Honolulu, HI 96813  
Mailing Address: P.O. Box 3469, Honolulu, HI 96801  
Access this form via website at: [cca.hawaii.gov/pvl](http://cca.hawaii.gov/pvl)

**PROGRAM SPONSOR AGREEMENT FOR CONTINUING EDUCATION ("CE")**

**PROGRAM TITLE:** Minimally Invasive Drop Instillation for Continuing Glaucoma Care

**INSTRUCTIONS**

1. Submit this original completed application form for each course title no more than 45 days after the course is completed;
2. Attach a program outline including time schedule;
3. Attach course description;
4. Attach curriculum vitae of all lecturer(s);
5. Attach a copy of the certificate of attendance (please see Hawaii Administrative Rules §16-92-40(a) for the required information); and
6. Attach a check for \$25 made payable to: "COMMERCE & CONSUMER AFFAIRS". (check must be in U.S. dollars and be from a U.S. financial institution.)

**FOR OFFICE USE ONLY**

Index number 25-011  
Reviewed by P. Chiriz  
Approved by \_\_\_\_\_  
Amended date \_\_\_\_\_

**SPONSOR'S NAME:** Hawaii Vision Specialists

**PHONE NO.:** 808-333-3233

**EMAIL ADDRESS:** info@hawaiivisionspecialists.com

**TYPE OF ORGANIZATION:** Ophthalmology/Optometry

**BUSINESS ADDRESS:** 392 Kapiolani St

**LOCATION OF PROGRAM (City, State):** Hilo, HI

**DATE OF PROGRAM:** 6-5-2025

**Total CE hour(s) being requested:** 2

2 hours(s) will apply towards fulfilling the 36 hours of CE in the diagnosis, treatment and management of ocular and systemic diseases, required for license renewal of an optometrist with therapeutic pharmaceutical agent ("TPA") certification.

**The sponsor agrees that the program shall be such:**

1. That it will require and monitor the attendance;
2. That it will be at least 50 minutes in duration for each hour claimed from the beginning of the subject matter to its conclusion;
3. That it will be presented by a qualified lecturer, whose name, title, and qualifications are to be included in attached curriculum vitae;
4. That written records of its attendees and of the program outline shall be maintained in its files for a period of two years immediately following its conclusion;
5. That written evidence of attendance will be issued by the Sponsor to **each attendee** with the CE hour(s) and the Board's Hawaii Index Number shown thereon. The Board will not accept any certification of attendance or lists of attendees from the Sponsor. If any are received, they will be discarded;

(CONTINUED ON PAGE 2)



# Continuing Education Course Outline: Minimally Invasive Drop Instillation for Continuing Glaucoma Care

**Course Date:** June 5, 2025

**Speaker:** Dr. Bacarach, California Pacific Medical Center, San Francisco

**CE credit:** 2 hours

## Course Overview

- Focus: Reducing patient dependence on multiple eyedrops through advanced medications combining prostaglandin analogues and nitric oxide moieties.
- Complements advancements in minimally invasive glaucoma surgery (MIGS) with reduced medication dependency.

## Key Points

### 1. Role of Nitric Oxide in Glaucoma Treatment

- Nitric oxide relaxes the trabecular meshwork, enhancing aqueous outflow.
- Non-glaucomatous eyes have normal nitric oxide levels; reduced in glaucomatous eyes, especially with higher intraocular pressure (IOP).
- Goal: Administer combination therapies (nitric oxide + prostaglandin analogues) to target:
  - Scleral outflow pathway.
  - Traditional outflow mechanism (similar to selective laser trabeculoplasty).



### 2. Advanced Medications

- **Vyzulta (Latanoprostene Bunod):**
  - Approved in the U.S. in 2017.
  - Single drop with nitric oxide moiety, cleaved enzymatically into nitric oxide.
  - Not a combination drop, leading to better tolerability compared to combined prostaglandin and nitric oxide drops (e.g., latanoprost + netarsudil).
  - Lower discontinuation rates and higher potency than single-category prostaglandins.
  - Studies show significant IOP reduction post-washout when switched to Vyzulta.
  - Once-daily dosing; no additional efficacy with more frequent dosing.
  - Manufacturer: Bausch & Lomb.
- **Rocklatan:**
  - Combination medication containing latanoprost and netarsudil.



This certifies that

*Jana Miki'ala Souza, OD*

has successfully attended and completed

MINIMALLY INVASIVE DROP INSTILLATION FOR CONTINUING GLAUCOMA CARE

For 8 CE TPA Certification Credits

Course # 17-009

On June 5, 2025



Dan Driscoll, MD



HAWAII VISION SPECIALISTS

**Jason Bacharach, M.D.**  
**North Bay Eye Associates, Inc.**

*Main Office:*

*Research Department:*



## EDUCATION

College	Villanova University, Villanova, PA	1980-1984
Medical School	Hahnemann University Medical Center, PA	1984-1988
Internship	Crozer-Chester Medical & Burn Center, PA	1988-1989
Residency	Hahnemann University Medical Center, PA	1989-1992
Fellowship	Jules Stein Eye Institute, UCLA Medical Center, CA	1992-1993

## CERTIFICATION

California Medical Board	May 1992
American Board of Ophthalmology	May 1994

## CLINICAL APPOINTMENTS

<b>Medical Director &amp; Founder</b> , North Bay Eye Associates, Inc.	1993-Present
<b>Director of Clinical Research</b> , North Bay Eye Associates, Inc.	1993-Present
<b>Clinical Instructor &amp; Current Co-Director</b> , Glaucoma Section, CPMC Present (California Pacific Medical Center)	1994-
<b>Chief of Lion's Eye Glaucoma Clinics</b> , CPMC (California Pacific Medical Center)	2005-Present
<b>Medical Director</b> , Radius <sup>XR</sup> Present	2023-

## MEMBERSHIPS & HOSPITAL AFFILIATIONS

American Academy of Ophthalmology	1989-Present
American Glaucoma Society	1994-Present
California Medical Association	1993-
Present Ophthalmic Society of the Redwood Empire	1993-
Present Petaluma Valley Hospital ( <i>Surgical Executive Committee</i> )	1998-2001
North Bay Eye Associates Ambulatory Surgery Center	2000-Present
Congressional Glaucoma Caucus Foundation	2001-Present
Petaluma Valley Hospital ( <i>Executive Board</i> )	2001-
2006 Petaluma Valley Hospital ( <i>Chief of Staff</i> )	2003-2005
Petaluma Surgical Associates ( <i>Executive Board</i> )	2009-
Present	

## RESEARCH

University of Pennsylvania; Institute for Environmental Medicine, PA  
 Page 4 of 9



1980-1985

Sepataprost non-inferiority to timolol maleate in primary open angle glaucoma or ocular hypertension 2022

25-011

IOP at month 3 with travaprost intraocular implant vs IOP at screening while on prostaglandin analog monotherapy 2023

Clobetasol propionate ophthalmic suspension 0.05% for the treatment of postsurgical inflammation and pain (cpn-302) 2024

American Academy of Optometry

- Rocket-4 6-month analysis 2017

Effects of OTX-101, treatment on conjunctival and corneal staining at day 14; results of phase 2b/3 clinical trial 2022

American Glaucoma Society Annual Meeting

- New technology surgical symposium (presentation) 2009

The results from a multi-center, randomized trial comparing argon laser & titanium sapphire lasers 2009

Masked, randomized, parallel comparison of IOP-lowering efficacy after switching to bimatoprost 0.03% vs continuing with latanoprost 0.005% 2010

Second generation stents in mild-moderate open-angle glaucoma: design review and initial clinical data from prospective, randomized study 2011

Results through two years postoperative from prospective randomized studies of second-generation stents and cataract surgery in mild-moderate open-angle glaucoma 2012

Suprachoroidal stent and cataract surgery vs cataract surgery only for open-angle glaucoma: findings from a prospective, randomized, controlled multicenter study 2013

What patients know about glaucoma. Gaps in knowledge 2013

Double masked, randomized, dose-response study of AR-13324 ophthalmic solution compared to latanoprost in patients with elevated intraocular pressure 2014

Initial clinical evaluation of safety, tolerability & pharmacodynamics of locally-acting ROCK inhibitor AMA0076 2014

Evaluation of PG324, a fixed dose combination of AR-13324 and latanoprost, in patients with elevated IOP in a double-masked, randomized, controlled study 2015

Patients' attitudes towards generic versus brand-name Glaucoma eye drops 2015

AR-13324 ophthalmic solution 0.02%: topline results of two phase 3 clinical studies in patients with open-angle glaucoma and ocular hypertension 2016

Rho-kinase inhibitor update 2017

24-hour IOP control with brinzolamide 1%/brimonidine 0.2% in open-angle glaucoma or ocular hypertension 2018

Once-daily netarsudil 0.02% vs twice-daily timolol maleate 2018



American Society of Cataract and Refractive Surgery

Micro-incisional glaucoma surgery course instructor	2011-2024
Micro-incisional glaucoma presentation – “glaucoma day”	2013
Prospective randomized controlled multicenter study of supra-choroidal stent and cataract surgery vs cataract surgery alone for open-angle glaucoma	2013
Rock inhibitors: do they really rock?	2016
Five-year results of a prospective study of 2 trabecular	
2018	
bypass stents vs prostaglandin in newly diagnosed open-angle glaucoma	micro-
Medications-glaucoma wars: new hope medication protocol/ decision tree 2019	2019
Industry theater: excisional goniotomy using the KDB blade	2019
Industry theater: think outside the drop: Dexycu	2019
Evaluation of glaucoma using OCT angiography (co-author)	2019
Evaluating safety, tolerability and efficacy of an intracameral hydrogel-based travoprost implant in subjects with glaucoma phase 1 trial interim review	2020
Preservative free vs. preserved latanoprost 0.005% in patients with primary open-angle glaucoma or ocular hypertension	2023
The effect of eyedrop size on pupillary dilation using the nanodropper bottle adapter	2023
Next level visual field detection techniques	2023
Latanoprost alone or adjunctive therapy to netarsudil/latanoprost fixed-dose combination	2024
Travoprost intraocular implant: analysis of topical prostaglandin analog-associated adverse events	2024





Kiawah Eye

Dexycu symposium

2021

Morgan-Sarver Lecture, UC Berkeley School of Optometry

Post-pandemic glaucoma surgery update

2021

National Glaucoma Society

2024

Updates on glaucoma surgical and medical management

SOE

Effect of OTX-101 on corneal staining: pooled analysis

2019

Sonora Ophthalmologic Society, Hermosillo, Mexico

Management of advanced glaucoma

1994

Stanford Basic Science Course in Ophthalmology

Tonometry and gonioscopy

1997

Setons and cycloablation

1998-2001

Telling It Like It Is

2023

Novel VR VF and IOP diagnostic technologies

Tear Film and Ocular Surface Society (TFOS)

2024

Early symptom relief and satisfaction with  
perflourohexyloctane ophthalmic solution in patients with  
dry eye disease: results from a prospective, multicenter study

Women in Ophthalmology Annual Meeting

2021

Upper eyelid elevation in acquired ptosis with once-daily  
administration of topical oxymetazoline 0.1%: subgroup  
analysis based on pre-treatment ptosis severity

World Glaucoma Congress

Consistency of intraocular pressure response with latanoprost  
in ocular hypertensive patients

2005

Rock inhibitors, what do ophthalmologists think?

2019

World Ophthalmology Congress

Baseline characteristics of patients diagnosed with dry eye

2006



- IOVS Vol. 57-  
2016 "Impact of dry eye disease on work productivity, and patients' satisfaction with over-the-counter dry eye treatments"
- IOVS Vol.59-2018  
"Comparison of the change in intraocular pressure with a fixed-dose combination of brinzolamide 1% and brimonidine 0.2% vs brinzolamide or brimonidine alone in patients with open-angle glaucoma or ocular hypertension: post hoc pooled phase 3 analysis"
- Journal of Clinical Ophthalmology Vol. 12-  
2018 "A phase II/III, randomized, double-masked, vehicle-controlled, dose-ranging study of the safety and efficacy of OTX-101 in the treatment of dry eye disease."
- Ophthalmology Vol. 126-2019  
"24-hour intraocular control with fixed-dose combination brinzolamide 1%/brimonidine 0.2%: a multicenter, randomized trial"
- Journal of Clinical Ophthalmology Vol.  
13-2019 "A phase II/III randomized, double-masked, vehicle-controlled, dose ranging study of the safety and efficacy of OTX-101 in the treatment of dry eye disease"
- Cornea Vol. 38-2019  
"Effect of OTX-101, a novel nanomicellar formulation of cyclosporine A, on corneal staining in patients with keratoconjunctivitis sicca"
- Eye and Contact Lens Vol.  
46-2019 "Efficacy and safety of OTX-101, a novel nanomicellar formulation of cyclosporin A, for the treatment of keratoconjunctivitis sicca: pooled analysis of a phase 2b/3 and phase 3 study"
- American Journal of Ophthalmology Vol. 204-2019  
"Once-daily netarsudil versus twice-daily timolol in patients with elevated intraocular pressure: the randomized phase 3 rocket-4 study"
- Journal of Clinical Ophthalmology Vol. 14-  
2020 "Managing dry eye disease and facilitating realistic patient expectations: a review and appraisal of current therapies"
- Advances in Therapy Vol 37-  
2020 "Fixed-dose combination of netarsudil and latanoprost in ocular hypertension and open-angle glaucoma: pooled efficacy/safety analysis of phase 3 mercury-1 and -2"
- Journal of Cataract and Refractive Surgery Vol 47-  
2021 "Impact of dexamethasone intraocular suspension 9% on intraocular pressure after routine cataract surgery: post hoc analysis"
- Journal of Cataract and Refractive Surgery Online Case Reports Vol 9-  
2021 "Oxymetazoline for the treatment of speculum induced blepharoptosis"
- Journal of Clinical Ophthalmology Vol 5-  
2021 "Eyecare practices and glaucoma patient care trends in the face of a global pandemic, covid-19"





# **HONORS, COMMITTEE and PROFESSIONAL APPOINTMENTS**

American Academy of Ophthalmology	
Achievement Award	2005
Secretariat Award	2013
Senior Achievement Award	2024
American Board of Ophthalmology Examiner	2005-
Present	
Advisory Board, <i>Imprimis Pharmaceuticals</i>	2020-
present	
Advisory Board, <i>Injectsense</i>	2019-present
American Society of Cataract and Refractive Surgery	2024-present
Glaucoma Clinical Care Committee	
Editorial Board, <i>Ophthalmology 360</i>	2020-present
Editorial Board, <i>Advanced Ocular Care</i>	2009-
2018	
Ophthalmology Resident Teaching Award, Cal Pacific Medical Center	2003, 2006
Ophthalmic Knowledge Based Panel for Glaucoma, ( <i>chair</i> )	2003-2013
American Academy of Ophthalmology	
Optometric Glaucoma Society: <i>President's Lecturer Award</i>	2024
Reviewer, <i>American Journal of Ophthalmology</i>	2003-
Present	
Reviewer, <i>BMC Ophthalmology</i>	2021-
Present	
Reviewer, <i>Current Eye Research</i>	2008-
Present	
Reviewer, <i>Journal of Cataract &amp; Refractive Surgery</i>	2017-Present
Reviewer, <i>Journal of Glaucoma</i>	2019-
Present	
Reviewer, <i>Ophthalmology, Glaucoma</i>	2019-
Present	
Reviewer, <i>Henry Journal of Case Reports and Imaging</i>	2021-
Present	



State of Hawaii  
 Department of Commerce and Consumer Affairs  
**HAWAII BOARD OF OPTOMETRY**  
 335 Merchant St., 3rd Floor, Honolulu, HI 96813  
 Mailing Address: P.O. Box 3469, Honolulu, HI 96801  
 Access this form via website at: [cca.hawaii.gov/pvl](http://cca.hawaii.gov/pvl)

**PROGRAM SPONSOR AGREEMENT FOR CONTINUING EDUCATION ("CE")**

**PROGRAM TITLE:** A Year with iDose: Moving Beyond Traditional Eye Drops

**INSTRUCTIONS**

1. Submit this original completed application form for each course title no more than 45 days after the course is completed;
2. Attach a program outline including time schedule;
3. Attach course description;
4. Attach curriculum vitae of all lecturer(s);
5. Attach a copy of the certificate of attendance (please see Hawaii Administrative Rules §16-92-40(a) for the required information); and
6. Attach a check for \$25 made payable to: "COMMERCE & CONSUMER AFFAIRS". (check must be in U.S. dollars and be from a U.S. financial institution.)

**FOR OFFICE USE ONLY**

Index number 25-012  
 Reviewed by PChin  
 Approved by \_\_\_\_\_  
 Amended date \_\_\_\_\_



**SPONSOR'S NAME:** Hawaii Vision Specialists

**PHONE NO.:** 808-333-3233

**EMAIL ADDRESS:** info@hawaiivisionspecialists.com

**TYPE OF ORGANIZATION:** ophthalmology/optometry

**BUSINESS ADDRESS:** 392 Kapiolani St

**LOCATION OF PROGRAM (City, State):** Hilo, HI

**DATE OF PROGRAM:** 7/17/2025

**Total CE hour(s) being requested:** 2

2 hours(s) will apply towards fulfilling the 36 hours of CE in the diagnosis, treatment and management of ocular and systemic diseases, required for license renewal of an optometrist with therapeutic pharmaceutical agent ("TPA") certification.

**The sponsor agrees that the program shall be such:**

1. That it will require and monitor the attendance;
2. That it will be at least 50 minutes in duration for each hour claimed from the beginning of the subject matter to its conclusion;
3. That it will be presented by a qualified lecturer, whose name, title, and qualifications are to be included in attached curriculum vitae;
4. That written records of its attendees and of the program outline shall be maintained in its files for a period of two years immediately following its conclusion;
5. That written evidence of attendance will be issued by the Sponsor to **each attendee** with the CE hour(s) and the Board's Hawaii Index Number shown thereon. The Board will not accept any certification of attendance or lists of attendees from the Sponsor. If any are received, they will be discarded;

(CONTINUED ON PAGE 2)

Print Name of Sponsor: Hawaii Vision SpecialistsDate: 7/18/2025

6. That the CE hour(s) requested are exclusive of any preparation time;
7. That the program records will be subject to review by the Hawaii Board of Optometry ("Hawaii Board") and the program sponsor agrees to make these records available to the Hawaii Board or its designee during regular business hours at the business address indicated on this application for a period of two years following the date of presentation; and
8. That the Hawaii Board will be notified as to the location of these records if they are removed from the above location prior to expiration of the above two year period.

In consideration for compliance with this agreement, we understand that we may advise prospective attendees of the approval of our program and the number of hours of credit allowable. If we fail to comply with this agreement or fail to meet acceptable standards in our program, we understand that approval of our program may be revoked by the Hawaii Board and that notice of such revocation may be given by the Hawaii Board to all licensees.

By   
Signature of individual responsible for CE administration

7/18/2025

Date

Its OD/MD  
Title

Jana M Souza, OD/Dan Driscoll, MD

Print name of individual responsible for CE administration

**(THIS FORM MAY BE DUPLICATED)**

Print Form

This material can be made available for individuals with special needs. Please call the Licensing Branch Manager at (808) 586-3000 to submit your request.

## **A Year with iDose: Moving Beyond Traditional Eye Drops**

This outline is designed for a two-hour educational meeting aimed at providing referring doctors with insights into the latest advancements in glaucoma treatment, focusing on innovative solutions beyond traditional eye drops.

### **Hour 1: Understanding the Current Landscape and Challenges in Glaucoma Treatment**

#### **1. Introduction to Glaucoma Treatment**

- Historical perspective on glaucoma management
- Perception of eye drops as a risk-averse treatment

#### **2. Challenges with Eye Drops**

- Patient compliance and non-adherence issues
- Impact of complex dosing regimens on quality of life

#### **3. Emerging Alternatives to Eye Drops**

- Overview of new technologies: lasers, MIGs, goniotomies
- Introduction to interventional glaucoma approaches

#### **4. Data on Patient Compliance**

- Statistics on non-compliance and discontinuation of drops
- Discussion on patient follow-up and compliance with interventions

#### **5. Interventional Glaucoma in Practice**



- Moving away from legacy treatment sequences
- Role of minimally invasive glaucoma surgeries (MIGS)

## 6. Case Studies and Data Analysis

- Examination of patient outcomes with various interventions
- Discussion on the effectiveness of drug delivery systems

## Hour 2: Exploring Innovative Solutions and Future Directions

### 1. Introduction to iDose TR

- Description and mechanism of the iDose TR implant
- Comparison with traditional prostaglandin drops

### 2. Clinical Data and Efficacy

- Overview of Phase 3 trials and long-term follow-up data
- Discussion on pharmacokinetics and drug elution

### 3. Patient Selection and Dialogue

- Identifying suitable candidates for iDose TR
- Effective communication strategies with patients

### 4. Safety and Adverse Events

- Common adverse events and management strategies
- Endothelial cell density and long-term safety data

## 5. Economic Considerations and Reimbursement

- Overview of reimbursement strategies for iDose TR
- Discussion on procedural pharmaceutical classification

## 6. Future Innovations and Research

- Upcoming developments: iDose T-Rex and corneal cross-linking
- Potential for synergistic effects with other treatments

## 7. Q&A and Closing Remarks

- Addressing questions from attendees
- Summary of key takeaways and future outlook





## Contact

**Omar Sadruddin, MD MBA**

Vice President, Global Medical Affairs at Glaukos  
Aliso Viejo, California, United States

**Experience****Glaukos Corporation**

Vice President, Global Medical Affairs  
October 2022 - Present (1 year 10 months)  
Aliso Viejo, California, United States

**Santen Pharmaceutical**

5 years

**Therapeutic Area Head, Glaucoma**

2019 - October 2022 (3 years)  
San Francisco Bay Area

**Global Medical Director**

2017 - 2019 (2 years)  
Emeryville, CA

**Alcon, a Novartis company****Global Clinical Director**

2014 - 2017 (3 years)  
Dallas/Fort Worth Area

**St. Jude Medical**

3 years

**Senior Clinical Program Manager**


2013 - 2014 (1 year)  
Greater Minneapolis-St. Paul Area

**Clinical Trial Manager**

2011 - 2013 (2 years)  
Greater Minneapolis-St. Paul Area

**Cedars-Sinai****Senior Postdoctoral Fellow**

2009 - 2011 (2 years)

**Top Skills**

Clinical Research  
Cardiology  
Clinical Trials

**Languages**

English (Full Professional)  
Spanish (Limited Working)  
Hindi (Professional Working)

**Publications**

Heart-rate adjustment of transcatheter haemodynamics improves the prognostic evaluation of paravalvular regurgitation after transcatheter aortic valve implantation.

Transfemoral Access Assessment for Transcatheter Aortic Valve Replacement

Ab externo implantation of the MicroShunt, a poly (styrene-block-isobutylene-block-styrene) surgical device for the treatment of primary open-angle glaucoma: a review

Safety and Effectiveness of the PRESERFLO® MicroShunt in Primary Open-Angle Glaucoma: Results from a 2-Year Multicenter Study

4- and 5-Year Results of the MicroShunt in Patients with Primary Open-Angle Glaucoma

## Education

Liberty University

Master of Business Administration - MBA, Health/Health Care Administration/  
Management · (2013)

ASU School of Medicine

Doctor of Medicine - MD · (2006)

This certifies that

Jana Miki'ala Souza, OD

has successfully attended and completed

A YEAR WITH IDOSE: MOVING BEYOND TRADI-  
TIONAL EYE DROPS

For 2 CE TPA Certification Credits

Course # 00-000

On July 17, 2025



Dan Driscoll, MD

State of Hawaii  
Department of Commerce and Consumer Affairs  
**HAWAII BOARD OF OPTOMETRY**  
335 Merchant St., 3rd Floor, Honolulu, HI 96813  
Mailing Address: P.O. Box 3469, Honolulu, HI 96801  
Access this form via website at: [cca.hawaii.gov/pvl](http://cca.hawaii.gov/pvl)

**PROGRAM SPONSOR AGREEMENT FOR CONTINUING EDUCATION ("CE")**


**PROGRAM TITLE:** Refractive Technology and Co-Management Update 2025

**INSTRUCTIONS**

1. Submit this original completed application form for each course title no more than 45 days after the course is completed;
2. Attach a program outline including time schedule;
3. Attach course description;
4. Attach curriculum vitae of all lecturer(s);
5. Attach a copy of the certificate of attendance (please see Hawaii Administrative Rules §16-92-40(a) for the required information); and
6. Attach a check for \$25 made payable to: "COMMERCE & CONSUMER AFFAIRS". (check must be in U.S. dollars and be from a U.S. financial institution.)

**FOR OFFICE USE ONLY**

Index number 25013  
Reviewed by PCH  
Approved by \_\_\_\_\_  
Amended date \_\_\_\_\_



**SPONSOR'S NAME:** Aloha Laser Vision

**PHONE NO.:** 808-792-3937

**EMAIL ADDRESS:** [REDACTED]

**TYPE OF ORGANIZATION:** Private Ophthalmology Practice

**BUSINESS ADDRESS:** 1100 Ward Avenue Suite 1000; Honolulu, HI 96814

**LOCATION OF PROGRAM (City, State):** Honolulu, HI (Zoom)

**DATE OF PROGRAM:** 8/20/2025

**Total CE hour(s) being requested:** 1

1 hours(s) will apply towards fulfilling the 36 hours of CE in the diagnosis, treatment and management of ocular and systemic diseases, required for license renewal of an optometrist with therapeutic pharmaceutical agent ("TPA") certification.

**The sponsor agrees that the program shall be such:**

1. That it will require and monitor the attendance;
2. That it will be at least 50 minutes in duration for each hour claimed from the beginning of the subject matter to its conclusion;
3. That it will be presented by a qualified lecturer, whose name, title, and qualifications are to be included in attached curriculum vitae;
4. That written records of its attendees and of the program outline shall be maintained in its files for a period of two years immediately following its conclusion;
5. That written evidence of attendance will be issued by the Sponsor to **each attendee** with the CE hour(s) and the Board's Hawaii Index Number shown thereon. The Board will not accept any certification of attendance or lists of attendees from the Sponsor. If any are received, they will be discarded;

(CONTINUED ON PAGE 2)

Print Name of Sponsor: Aloha Laser VisionDate: 7/18/2025

6. That the CE hour(s) requested are exclusive of any preparation time;
7. That the program records will be subject to review by the Hawaii Board of Optometry ("Hawaii Board") and the program sponsor agrees to make these records available to the Hawaii Board or its designee during regular business hours at the business address indicated on this application for a period of two years following the date of presentation; and
8. That the Hawaii Board will be notified as to the location of these records if they are removed from the above location prior to expiration of the above two year period.

In consideration for compliance with this agreement, we understand that we may advise prospective attendees of the approval of our program and the number of hours of credit allowable. If we fail to comply with this agreement or fail to meet acceptable standards in our program, we understand that approval of our program may be revoked by the Hawaii Board and that notice of such revocation may be given by the Hawaii Board to all licensees.

By   
Signature of individual responsible for CE administration

7/18/2025  
Date

Its \_\_\_\_\_  
Optometrist  
Title

Elizabeth-Rose Hanohano-Hong, OD

\_\_\_\_\_  
Print name of individual responsible for CE administration

**(THIS FORM MAY BE DUPLICATED)**

Print Form



This material can be made available for individuals with special needs. Please call the Licensing Branch Manager at (808) 586-3000 to submit your request.



**Program: Refractive Technology and Co-Management Update 2025**

**Program Date: 8/20/2025**

**Speaker: Alan R. Faulkner, MD**

## **Program Outline and Time Schedule**

5:45 – 6:00 Check-in

6:00 – 6:50 "Refractive Technology and Co-Management Update 2025" lecture

6:50 – 7:00 Q&A

7:00 End of meeting

## **Course Description**

The next generation of LASIK is here! Wavelight Plus is an exciting new LASIK platform from Alcon, which is showing promising results of visual acuity and quality of vision by correcting refractive error and higher-order aberrations. The EVO ICL by Staar Surgical is still an excellent option for patients with moderate to high myopia who would like to be free of corrective eye wear. In the world of intraocular lenses, there have been three new trifocals released in the past year, the Tecnis Odyssey, Envista Envy, and PanOptix Pro, giving patients more options for full range of vision. Patient candidacy and case studies will be discussed for both LASIK and full range of focus intraocular lenses.



1100 WARD AVENUE SUITE 1000 HONOLULU, HAWAII 96814 ✦ PHONE: 808.792.3937 FAX: 808.599.4818

Alan R. Faulkner, MD ✦ Ryan Steck, DO ✦ Kathryn Mau, OD ✦ Elizabeth Hanohano-Hong, OD ✦ Jordan Schmerbauch, OD



**ALAN R. FAULKNER, M.D., F.A.A.O.****EMPLOYMENT HISTORY**

Aloha Laser Vision, LLC <i>Founder, Medical Director</i> 1100 Ward Avenue, Suite 1000 Honolulu, HI 96814	Jan 2002 - present
The Surgical Suites, LLC <i>Co-owner, Managing Director</i> 1100 Ward Avenue, Suite 1010 Honolulu, HI 96814	Jan 2005 - present
Faulkner Eye Care & Surgery <i>Ophthalmologist</i> 1100 Ward Avenue, Suite 1000 Honolulu, HI 96814	May 2000 – Dec 2001
Eye Associates of West Jefferson <i>Ophthalmologist</i> 1111 Medical Center Blvd., N-213 Marrero, LA 70072	Aug 1998 – Apr 2000
Medical & Surgery Eye Center <i>Ophthalmologist</i> 1051 Gause Blvd., Suite 480 Slidell, LA 70458	Aug 1998 – Apr 2000
Tulane University Medical School <i>Assistant Professor of Ophthalmology</i> Department of Ophthalmology 1430 Tulane Avenue New Orleans, LA 70131	Jul 1991 – Aug 1998
Valley Supply Company <i>Salesman / Business Owner</i> West Des Moines, IA	Jan 1977 – Aug 1980

**EDUCATION**

Northwestern University, Kellogg School of Management Evanston, IL Physician CEO	Sept 2015
Tulane University School of Medicine New Orleans, LA Medical Doctorate	May 1986
University of Hawaii at Manoa Honolulu, HI	May 1982
Northwestern University Evanston, IL B.A. Sociology	Aug 1976



Tulane University  
New Orleans, LA

Dec 1973

### **POST-GRADUATE TRAINING**

Internship	June 1987
Tulane Affiliated Hospitals	
Department of Medicine, Preliminary Internal Medicine	
New Orleans, LA	
Residency	June 1990
Tulane Affiliated Hospitals	
Department of Ophthalmology	
New Orleans, LA	
Fellowship	June 1991
Tulane University School of Medicine	
Department of Ophthalmology	
Oculoplastic, Orbit, and Ophthalmic Oncology Fellowship	
Barrett G. Haik, MD & Thomas Naugle, MD	
New Orleans, LA	

### **LICENSURE & CERTIFICATION**

American Board of Ophthalmology	Nov 1991
Lifetime Certificate	
State of Louisiana Medical License	1986 – 2002
#018763 (Inactive)	
State of Hawaii Medical License	2000 – present
#MD-10871	

### **HONORS & ACTIVITIES**

- Best Doctors
- OSN Premier Surgeon 300 Innovators in Refractive Cataract Surgery, 2016
- Senior Year Medical School Revision Committee, Tulane University School of Medicine, 1994
- Institutional Committee on Graduate Medical Education, Tulane University School of Medicine, Jul 1994 – Dec 1997
- Southern Eye Bank, New Orleans, LA
  - Board Member/Medical Director, Aug 1994 – Mar 2000
  - Secretary of the Board, Jan 1999 – Mar 2000
- Skill Examiner for Joint Commission of Allied Health Personnel in Ophthalmology, 1992 – 1998
- Medical School Admissions Committee, Tulane University School of Medicine, 1984 – 1986
- Treasurer, American Medical Student Association, Tulane University Chapter, 1983 – 1984
- Co-chairman of Applicant Housing Committee, Student Advisory Board to Admissions at Tulane University School of Medicine, 1983 – 1984
- President of Student Advisory Board, 1984 – 1985
- Alpha Omega Alpha – Medical School Honor Society



**ACADEMIC APPOINTMENTS**

---

Clinical Assistant Professor of Ophthalmology Tulane Medical School, Department of Ophthalmology	Aug 1998 – May 2000
Assistant Professor of Ophthalmology, Full-time Faculty Tulane Medical School, Department of Ophthalmology	Jul 1991 – Aug 1998

**PROFESSIONAL ASSOCIATIONS**

---

American Academy of Ophthalmology, Fellow  
 American Society of Cataract and Refractive Surgery  
 American-European Congress of Ophthalmic Surgery, Founding Member  
 Hawaii Ophthalmological Society

**PROFESSIONAL ACTIVITIES**

---

Hawaiian Eye Foundation  
 Scientific Advisory Board, 2014 – 2016  
 Board Member, 2016 – present

**INDUSTRY ASSOCIATIONS (current and past)**

---

Acufocus – speaker  
 Alcon – speaker, consultant, research  
 Avedro – consultant  
 Bausch & Lomb – speaker, consultant  
 LenSx – clinical trials  
 Omeros – consultant  
 Refocus – clinical research  
 Shire – speaker  
 Wavetec – speaker, consultant, clinical trials

**PRESENTATIONS and MEETING FACULTY**

---

AECOS Aspen – multiple presentations/panels/multiple meetings  
 AECOS Deer Valley – multiple presentations/panels/multiple meetings  
 ESCRS – numerous presentations of own and for others  
 Hawaiian Eye Meeting – 2013 to present  
 ISRS – AAO 2014  
 National Medical Association – Honolulu Meeting  
 OSN New York – 2012 – 2016  
 OSN Rome/Milan – 2011, 2013 – 2015



## **PUBLICATIONS**

---

Jacob-Labarre JT, Faulkner A, Kargioglul Z, Gordon R: Polymeric Patches to Prevent Muscle Adhesions. Association for Research in Vision and Ophthalmology (ARVO). Invest Ophthalmol Vis Suppl 30:131, 1989.

Ainbinder DJ, Faulkner AR, Haik BG: Review of Orbital Tumors. Current Opinion in Ophthalmology 2:3, 1991.

Fry C, Faulkner AR: Transactions of the New Orleans Academy of Ophthalmology, 1999. Kugler Publishing, 2000.

Wang, MX, Refractive Lens Exchange: A Surgical Treatment for Presbyopia, 2016. Chapter co-author: Keratorefractive Enhancement After Refractive Lens Exchange.

## **CLINICAL TRIAL EXPERIENCE**

---

STAAR Surgical Company – CP22-01, Post-Market Evaluation of the EVO ICL. 2022 to 2024.

STAAR Surgical Company – CP18-02, Post-Approval Study of the Visian Toric Implantable Collamer Lens. 2022 to 2025.

STAAR Surgical Company – CP19-01, A Multicenter Clinical Evaluation of the EVO/EVO+ Visian Implantable Collamer Lens. 2020 to 2024.

Refocus Group, Inc., Protocol Number VIS-2014, A Prospective, Multicenter Clinical Trial Of The VisAbility Implant System For Improvement Of Near Visual Acuity In Presbyopic Patients. 2014 – 2017.

Refocus Group, Inc., Protocol Number VIS-2014-5YR, A Prospective, Multicenter Clinical Trial Of The VisAbility™ Micro Insert System For The Improvement of Near Visual Acuity In Presbyopic Subjects – Long-Term Follow-Up. 2018 – 2021.

WaveTec Vision Systems, Inc., Protocol Number WA-13-001, A Multi-Center, Prospective, Randomized, Contralateral, Observer-Masked, Comparison of 1-Month Postoperative Refractive Outcomes between Intraoperative Measurements Obtained with the Optiwave Refractive Analysis System (ORA System® with VerifEye) Combined with Implantation of an Alcon Toric IOL and standard biometry and Alcon Toric IOL implantation. 2014.

Alcon LenSx, Inc., Protocol Number CPT-006m, Evaluation of a Modified Disposable Contact Lens Patient Interface for the LenSx Laser in Cataract and Corneal Surgery. 2012.





# CERTIFICATE OF CONTINUING EDUCATION

This Acknowledges That

## Participant Name

Has Successfully Completed

"Refractive Technology and Co-Management Update 2025"

Course ID: XX-XXX, 1 Credit Hour of TPA Certification

Honolulu, HI (Zoom Live Webinar)

A handwritten signature in black ink, appearing to read "Alan R. Faulkner MD".

**ALAN R. FAULKNER, MD**

**BOARD CERTIFIED OPHTHALMOLOGIST**





State of Hawaii  
Department of Commerce and Consumer Affairs  
**HAWAII BOARD OF OPTOMETRY**  
335 Merchant St., 3rd Floor, Honolulu, HI 96813  
Mailing Address: P.O. Box 3469, Honolulu, HI 96801  
Access this form via website at: [cca.hawaii.gov/pvl](http://cca.hawaii.gov/pvl)

**PROGRAM SPONSOR AGREEMENT FOR CONTINUING EDUCATION ("CE")**

**PROGRAM TITLE:** Hawaii Optometric Association Live Virtual CE

**INSTRUCTIONS**

1. Submit this original completed application form for each course title no more than 45 days after the course is completed;
2. Attach a program outline including time schedule;
3. Attach course description;
4. Attach curriculum vitae of all lecturer(s);
5. Attach a copy of the certificate of attendance (please see Hawaii Administrative Rules §16-92-40(a) for the required information); and
6. Attach a check for \$25 made payable to: "COMMERCE & CONSUMER AFFAIRS". (check must be in U.S. dollars and be from a U.S. financial institution.)

**FOR OFFICE USE ONLY**

Index number 25-014  
Reviewed by PChap  
Approved by \_\_\_\_\_  
Amended date \_\_\_\_\_

**SPONSOR'S NAME:** Hawaii Optometric Association

**PHONE NO.:** 808-537-5678

**EMAIL ADDRESS:** hoapt@earthlink.net

**TYPE OF ORGANIZATION:** Professional Association

**BUSINESS ADDRESS:** 98-820 Moanalua Rd., #15-1/179; Aiea, Hawaii 96701

**LOCATION OF PROGRAM (City, State):** Honolulu, Hawaii


**DATE OF PROGRAM:** September 21, 2025

**Total CE hour(s) being requested:** 4

4 hours(s) will apply towards fulfilling the 36 hours of CE in the diagnosis, treatment and management of ocular and systemic diseases, required for license renewal of an optometrist with therapeutic pharmaceutical agent ("TPA") certification.

**The sponsor agrees that the program shall be such:**

1. That it will require and monitor the attendance;
2. That it will be at least 50 minutes in duration for each hour claimed from the beginning of the subject matter to its conclusion;
3. That it will be presented by a qualified lecturer, whose name, title, and qualifications are to be included in attached curriculum vitae;
4. That written records of its attendees and of the program outline shall be maintained in its files for a period of two years immediately following its conclusion;
5. That written evidence of attendance will be issued by the Sponsor to **each attendee** with the CE hour(s) and the Board's Hawaii Index Number shown thereon. The Board will not accept any certification of attendance or lists of attendees from the Sponsor. If any are received, they will be discarded;



(CONTINUED ON PAGE 2)




Print Name of Sponsor: Hawaii Optometric AssociationDate: July 25, 2025

6. That the CE hour(s) requested are exclusive of any preparation time;
7. That the program records will be subject to review by the Hawaii Board of Optometry ("Hawaii Board") and the program sponsor agrees to make these records available to the Hawaii Board or its designee during regular business hours at the business address indicated on this application for a period of two years following the date of presentation; and
8. That the Hawaii Board will be notified as to the location of these records if they are removed from the above location prior to expiration of the above two-year period.

In consideration for compliance with this agreement, we understand that we may advise prospective attendees of the approval of our program and the number of hours of credit allowable. If we fail to comply with this agreement or fail to meet acceptable standards in our program, we understand that approval of our program may be revoked by the Hawaii Board and that notice of such revocation may be given by the Hawaii Board to all licensees.

By



Signature of individual responsible for CE administration

July 25, 2025

Date

Its Executive Director

Title

Charlotte Nekota

---


 Print name of individual responsible for CE administration

(THIS FORM MAY BE DUPLICATED)

Print Form



This material can be made available for individuals with special needs. Please call the Licensing Branch Manager at (808) 586-3000 to submit your request.



# HAWAII OPTOMETRIC ASSOCIATION

DATE 9/21/2025 PLACE Honolulu HOURS 4

COURSE NAME Hawaii Optometric Association Live Virtual CE

INSTRUCTOR Drs. Neal Atebara; John Olkowski; Kristin Hirabayashi


This form, properly signed by the H.O.A. Education Chairman and an Education Session Assistant verifies attendance at the above course by:

(NAME OF ATTENDEE) \_\_\_\_\_

Attest Education Assistant \_\_\_\_\_

Education Chairman \_\_\_\_\_

(Submit with license renewal)



**Please join us for our live virtual event for 4 hours of TPA continuing education credits via ZOOM**

**Date: Sunday, September 21, 2025**

**Time: 9:00 am – 1:00 pm**

**Speakers**

**Dr. Neal Atebara—Retina Updates and Case Presentations**

**Dr. John Olkowski, Dr. Kristin Hirabayashi**

**Keratoconus Management: Collagen Cross-Linking and CTAK**



**Cost: HOA Members \$50 Non-Members: \$150**

**Please make check payable to: Hawaii Optometric Association**

**Mail to: Hawaii Optometric Association**

**98-820 Moanalua Rd., Unit 15-1/179**

**Aiea, HI 96701**

**Ph: (808) 537-5678 Fax: (808) 537-1509 E-Mail: hoapt@earthlink.net**

**\*\*A link to the seminar will be emailed to you\*\***

**\*\*Please RSVP by September 15, 2025\*\***

**MAHALO TO OUR SPONSOR**

**vsp VISION**

**Registration information: Please submit with your Payment**



**Name: \_\_\_\_\_ HOA Member \_\_\_\_\_**

**Mailing Address: \_\_\_\_\_**

**Email: \_\_\_\_\_ Phone: \_\_\_\_\_**

**If you would like to pay with a credit card, please call Charlotte Nekota at (808) 537-5678**

**September 21, 2025**

Dr. Neal Atebara:

Retinal Cases that cover a variety of diseases such as metabolic issues, trauma and aging. This will discuss surgical intervention as well as pharmacological treatments.



**Neal H. Atebara, M.D.**

**Curriculum Vitae, updated 2021-10-19**

Biographical

Born

Marital Status

Home Address



Business Address      Retinal Center of Hawaii, LLC  
Queen's Physician Office Building I  
1380 Lusitana Street, Suite 201  
Honolulu, Hawaii 96813  
tel. (808) 550-8440  
fax (808) 550-8488  
e-mail: [natebara@gmail.com](mailto:natebara@gmail.com)

Education and Work Experience

2000 - present      **Retina Center of Hawaii, LLC**  
Self-employed as vitreoretinal specialist  
Honolulu, Hawaii

1997 - 2000      **Retina Associates of Hawaii, Inc.**  
Employed as vitreoretinal specialist



Honolulu, Hawaii

1995 - 1997

**Barnes Retina Institute**

Washington University School of Medicine

Vitreoretinal Fellowship

St. Louis, Missouri

1992 - 1995

**Wills Eye Hospital**

Thomas Jefferson Medical School

Ophthalmology Residency

Philadelphia, Pennsylvania

1991 - 1992

**New England Deaconess Hospital**

Harvard Medical School

Medical Internship

Boston, Massachusetts

1986 - 1991

**Harvard Medical School**

M.D., *Magna cum laude*

Boston, Massachusetts

1982 - 1986

**Yale University**

B.S. in biology, *Magna cum laude*

New Haven, Connecticut

Summer 1985

**National Institutes of Health**

National Institute of Allergy and Infectious Diseases

Biomedical Research Fellowship

Bethesda, Maryland

1978 - 1982

**Waiakea High School**

Co-valedictorian, National Merit Scholar

Hilo, Hawaii





Honors and Awards

2021	Emeritus Chair, Hawaii Academy of Science
2021	National Outstanding Eagle Scout Award (NOESA), National Eagle Scout Association, Boy Scouts of America
2021	Silver Beaver Award, Boy Scouts of America
2019	District Service Award, Boy Scouts of America
2017	Hokupa'a Award, Boy Scouts of America
2005-present	Best Doctors in America, Best Doctors
2005-present	Best Doctors, Honolulu Magazine
2002-present	America's Top Ophthalmologists, Consumer's Research Council of America
2008-present	Cambridge Who's Who
2013	Most Compassionate Doctor, American Registry
2013	Top Ophthalmologists in Honolulu (International Association of Healthcare Professionals (IAHCP)
2013	Leading Physicians of the World
2011	Senior Achievement Award, American Academy of Ophthalmology
2010	Secretariat Award, American Academy of Ophthalmology
2007	Na Mea Kupaianaha O Waiakea
2003	American Academy of Ophthalmology Achievement Award
2002	Rhett Buckler Surgical Video Award
2001	Retina Society: elected member
1996	Heed Ophthalmic Foundation Research Grant
1994	Retina Research Foundation ARVO Grant
1991	<i>Magna Cum Laude</i> , Harvard Medical School
1989	Villee Research Grant, Harvard Medical School
1988	Paul Newman Grant for world blindness
1987	Harvard Medical School Student Research Grant
1986	<i>Magna Cum Laude</i> , Yale University
1985	Biomedical Research Fellowship, National Institutes of Health



Professional Background

**Academic Appointments**

2015 – present	Clinical Professor Division of Ophthalmology Department of Surgery John A. Burns School of Medicine University of Hawaii
1994 - 2001	Visiting Faculty Department of Ophthalmology Harvard Medical School
1997.	Associate Clinical Professor Department of Ophthalmology Washington University School of Medicine
1992.	Assistant Clinical Professor Department of Medicine Harvard Medical School

**Hospital Appointments**

1997 – present	Active Staff The Queen's Medical Center Honolulu, Hawaii
1997 – present	Courtesy Staff Kapiolani Medical Center for Women and Children Honolulu, Hawaii
1997 – present	Courtesy Staff Kuakini Medical Center



Dr. John Olkowski and Dr. Kristin Hirabayashi:  
Corneal Collagen Cross-linking and CTAK (Corneal Tissue Addition Keratoplasty) for the treatment of keratoconus. This will discuss patient selection for these procedures, how the procedures are performed, and the follow up requirements for successful outcome.



Dr. John Olkowski

Dr. Olkowski is the founder and chief surgeon of EyeSight Hawaii. He is a fellowship-trained [corneal surgery](#) specialist practicing in Hawaii since 1990. He has performed thousands of laser vision correction surgeries, even on other [LASIK](#) surgeons. He is experienced in [dry eye treatment](#), corneal, cataract, and laser vision correction surgeries including LASIK, [PRK](#), and VisianICL surgery.

#### EDUCATION & TRAINING

- Chief, Cornea Service, University of Hawaii – John A. Burns School of Medicine
- Tufts-New England Medical Center, Boston, Mass – Fellowship (corneal surgery specialty)
- George Washington University, Washington, DC – Residency in Ophthalmology
- Georgetown University School of Medicine – M.D.
- Georgetown University – B.S.





HOME ABOUT ▾ SERVICES ▾ SHOP PATIENT FORMS SCHEDULE APPOINTMENT

# KRISTIN HIRABAYASHI, MD

 Kristin Hirabayashi, MD

Kristin Hirabayashi, MD

 EVO Vision ICL Certified Surgeon



Dr. Kristin Hirabayashi is an ophthalmologist (eye surgeon) who specializes in cornea, cataract, and refractive eye surgery, such as [LASIK](#), [PRK](#), and [ICL](#). As a fellowship-trained cornea surgeon, she specializes in the diagnosis and management of cornea and ocular surface diseases, including corneal dystrophies, [keratoconus](#), pterygia, and [dry eye](#). She performs cataract surgery (with standard and advanced technology intraocular lenses, and laser [cataract surgery](#)), refractive eye surgery ([LASIK](#), [PRK](#), and [ICL](#)), corneal transplants, pterygium surgery, and crosslinking for [keratoconus](#).

Dr. Hirabayashi has personal ties to Hawaii as both her father and her husband grew up in Hawaii. In her free time, she loves to play volleyball, hike, go to the beach, travel, and spend time with her husband and two daughters. She is thrilled to be back in Honolulu and is grateful for the opportunity to provide care for such a wonderful community.





- Stanford University – Fellowship (corneal & external disease & refractive surgery)
- UCSF – Residency in Ophthalmology
- University of Hawaii – Internship
- UC Irvine – M.D. (Distinction in Research)
- Stanford University – B.A. Human Biology

## HONORS & AWARDS

- 2022 – Castle Connolly Rising Stars
- 2021 – Castle Connolly Rising Stars
- 2019 – Best paper of session at American Society of Cataract and Refractive Surgery
- 2018 – Langer Award for highest cumulative OKAP score in residency over 3 years
- 2013 – Junior Alpha Omega Alpha Honor Medical Society
- 2012 – Pathology Chairs Honor Society Member
- 2010 – Joshua Lederberg Award for Academic Excellence at Stanford

## BOARD CERTIFICATION

- American Board of Ophthalmology – Board certified

## PROFESSIONAL ORGANIZATIONS

- Hawaii Ophthalmological Society
- American Academy of Ophthalmology
- American Society of Cataract and Refractive Surgery
- Cornea Society
- Study Club for Ophthalmic Research in Hawaii (SCORH)





6.A.i\_Request for Trade Name




Tracie M. Inouchi, O.D.  
Sherry S. Y. Wong, O.D.  
Daniel M. Yamamoto, O.D.

eleven50 Building  
1150 S. King Street, Suite 201  
Honolulu, Hawaii 96814

T 808.949.2662  
F 808.947.0120  
simplyeyeshi.com

May 24, 2025

Hawaii Board of Optometry  
P.O. Box 3469  
Honolulu, HI 96801



Dear Hawaii Board of Optometry,

We have received your letter about updating the licensees mailing address. However, please update for Sherry S. Y. Wong as OD-1011 not OD-536. The other two licenses are correct.

We would also like to request from the Board for the use of "Simply Eyes Hawaii LLC."

Thank you,

Two handwritten signatures in blue ink. The first signature is 'Tracie' and the second is 'Sherry'.

Tracie Inouchi and Sherry S. Y. Wong  
Simply Eyes Hawaii

## 6.A.i\_Request for Trade Name



Tracie M. Inouchi, O.D.  
Sherry S. Y. Wong, O.D.  
Daniel M. Yamamoto, O.D.

Hawaii Board of Optometry  
P.O. Box 3469  
Honolulu, HI 96801

eleven50 Building  
1150 S. King Street, Suite 201  
Honolulu, Hawaii 96814

T 808.949.2662  
F 808.947.0120  
[simplyeyeshi.com](http://simplyeyeshi.com)

This letter is to inform the Hawaii Board of Optometry of a new business name:

Simply Eyes Hawaii LLC

1150 S King St, Suite 201

Honolulu, HI 96814

Please also update the three providers' mailing address to this practice:

Tracie M. Inouchi – NPI: [REDACTED]

Sherry S. Y. Wong – NPI: [REDACTED]

Daniel M. Yamamoto – NPI: [REDACTED]

Thank you,

Simply Eyes Hawaii LLC



# COPE<sup>®</sup> 2024

## Data Report



# COPE Accreditation

The Council on Optometric Practitioner Education (COPE®), established by the Association of Regulatory Boards of Optometry (ARBO), accredits continuing education on behalf of optometric regulatory boards. Continuing education (CE) is the primary method used by optometric regulatory boards to maintain the ongoing competence of licensed optometrists. COPE Accreditation serves the public, regulatory boards, and the profession by promoting improvements in competence, performance, and patient outcomes. Optometrists attend COPE accredited activities to earn CE credit for license renewal due to widespread acceptance of COPE CE by optometric licensing boards.

The COPE Governing Council is composed of representatives from the American Academy of Optometry (AAO), Association of Regulatory Boards of Optometry (ARBO), and Association of Schools and Colleges of Optometry (ASCO). This governing body sets the standards, policies, and procedures for the COPE accreditation program.

COPE offers two options for accreditation of optometric CE: Activity Accreditation and Provider Accreditation. CE providers may choose either accreditation option. Both Provider and Activity Accreditation follow the same COPE Accreditation Criteria and Standards for Integrity and Independence in Accredited Continuing Education (SII).

COPE's Accreditation Criteria and SII ensure that accredited CE is relevant, effective, evidence-based, and free from commercial bias. The COPE accreditation program ensures high-quality CE that meets rigorous standards for educational excellence and independence. This is ensured through COPE's adoption of the Accreditation Council for Continuing Medical Education (ACCME®) Accreditation Criteria and Standards for Integrity and Independence in Accredited Continuing Education (SII). This alignment allows COPE accredited optometric continuing education to be considered equal to the continuing medical education completed by medical doctors.



# COPE Mission Statement

COPE is committed to advancing the quality and integrity of optometric continuing education by upholding standards of excellence that lead to better patient care and improved health outcomes.

## COPE Objectives

The objectives of the Council on Optometric Practitioner Education (COPE) are:

- ▶ To accredit high-quality, competency-based optometric continuing education that addresses practice gaps, enhances professional practice and contributes to positive healthcare outcomes for patients and their communities.
- ▶ To establish clear and transparent processes for accreditation of continuing optometric education.
- ▶ To ensure the integrity and independence of all accredited continuing optometric education content that promotes evidence-based outcomes.
- ▶ To promote culturally competent accredited continuing optometric education.
- ▶ To provide a process for continuous quality improvement of COPE Administrators, Accredited Providers, and Reviewers.
- ▶ To assist and support regulatory boards by providing a trusted standardized accreditation process that ensures public protection.

# COPE Accreditation Process

COPE Activity Accreditation is a three-step process.

**1**

First, the educational material (course) is submitted for a formal review by licensed optometrists who volunteer as COPE Reviewers.

**2**

Second, the CE providers hosting the COPE CE submits activity information to COPE for review prior to the event, including the identified professional practice gaps, the educational needs of the learners, and the learning objectives of the activity.

**3**

Third, the CE provider submits educational outcomes information to COPE after completion of the activity.

**6,405** courses

**2,337** activities

In 2024, there were 6,405 courses and 2,337 activities submitted to COPE for review.

**429** COPE administrators/  
providers


**3,102** COPE accredited activities

There were 429 COPE Administrators/Providers who held 3,102 COPE accredited activities in 2024.


In 2024, the mean number of activities held by each COPE Administrator/Provider was 7, with a median of 2. There were 142 COPE Administrators/Providers that had one activity in 2024, while the maximum number of activities presented by one COPE Administrator/Provider was 319.



## Number of Courses Submitted to COPE Over Time



## Number of Activities Submitted to COPE Over Time



# COPE Course Categories

Each COPE Course is categorized into a generalized content area developed by COPE to meet the CE requirements for practitioner licensure of participating boards of optometry. The breakdown of courses by category in 2024 is below.

The COPE category definitions can be found at

[https://s3.amazonaws.com/arbo.org/public/cope\\_categories.pdf](https://s3.amazonaws.com/arbo.org/public/cope_categories.pdf)

COPE Category	Number of Courses	Percentage
Contact Lenses	317	4.95%
Ethics/Jurisprudence	62	0.97%
Functional Vision/Pediatrics	325	5.07%
General Optometry	686	10.71%
Glaucoma	624	9.74%
Injection Skills	14	0.22%
Laser Procedures	86	1.34%
Low Vision/Visual Impairment & Rehabilitation	110	1.72%
Neuro-Optometry	369	5.76%
Peri-Operative Management of Ophthalmic Surgery	500	7.81%
Pharmacology	310	4.84%
Practice Management	398	6.21%
Public Health	247	3.86%
Surgery Procedures (Optometric)	77	1.20%
Systemic/Ocular Disease	422	6.59%
Treatment/Management of Ocular Disease	1,858	29.01%
<b>Total</b>	<b>6,405</b>	

# COPE Course Formats

The course format refers to the method used to deliver educational content. Many licensing boards have specific requirements regarding which course formats are accepted for license renewal. COPE recognizes the following formats:



## Synchronous In-Person

The course instructor is in the same room as the participants. The instructor is face-to-face with the audience and can touch the participants.



## Synchronous Virtual

The course instructor is not physically present (not face-to-face) but is meeting with learners in real-time and can provide immediate feedback.



## Asynchronous

The course instructor and learner are not together at the same time, have no real-time communication, and the content is learner-paced.

## 2024 COPE Course Format Distribution

Format	Number of Courses	Percentage
Synchronous In-Person	4,223	65.9%
Synchronous Virtual	1,506	23.5%
Asynchronous	676	10.5%
Total	6,405	

## The Distribution of COPE Courses by Format from 2019-2024

Format	2024	2023	2022	2021	2020	2019
Synchronous In-Person	4,223 65.9%	4,193 65.3%	3,814 62.8%	4,433* 79.9%	3,813* 62.8%	5,097* 90%
Synchronous Virtual	1,506 23.5%	1,527 23.8%	1,637 26.9%	349* 6.3%	1,623* 26.7%	169* 3%
Asynchronous	676 10.5%	701 10.9%	622 10.2%	766 13.8%	622 10.2%	392 6.9%

\*Due to the COPE rule modification and state/provincial rule waivers for COVID-19, some courses submitted as live in 2019-2021 were presented as online/interactive.

# COPE Course Formats

A comparison of the format of courses submitted to COPE in 2024 versus the format of courses taken by optometrists in 2024 (from ARBO's *OE TRACKER*® program) is below.


## COPE Courses Submitted in 2024 by Format

Format	Number of Courses	Percentage
Synchronous In-Person	4,223	65.9%
Synchronous Virtual	1,506	23.5%
Asynchronous	676	10.5%
<b>Total</b>	<b>6,405</b>	

Synchronous In-Person

Synchronous Virtual

Asynchronous




## COPE Courses Taken in 2024 by Format (from *OE TRACKER*\*)

Format	COPE Accredited Courses	Non-Accredited Courses	Total	Percentage
Synchronous In-Person	315,681	47,833	363,514	46.9%
Synchronous Virtual	319,173	11,191	330,364	42.6%
Asynchronous	75,642	4,935	80,577	10.4%
<b>Total</b>	<b>710,496</b>	<b>63,959</b>	<b>774,455</b>	

Synchronous In-Person

Synchronous Virtual

Asynchronous




\*ARBO's *OE TRACKER*® program tracks continuing education credits for optometrists. The data in *OE TRACKER* can be accessed by optometrists and licensing boards online or on the *OE TRACKER* mobile app. Both COPE accredited and non-accredited courses are tracked by *OE TRACKER*. In 2024, there were almost 775,000 courses taken by optometrists added to *OE TRACKER*, and over 8,800,000 courses have been uploaded since the inception of the program.

# COPE Administrators and Accredited Providers


In 2024, COPE had 401 Administrators, 2 Accredited Providers, and 26 Jointly Accredited Providers who presented 3,102 COPE accredited CE activities. The COPE accreditation system is international in scope with COPE Administrators/Providers located in the US, Canada, Australia, China, and the United Kingdom.

## COPE Administrator/Provider Locations




# COPE Administrators and Accredited Providers

US Locations



Canadian Locations






# The Scope of COPE Administrators/Providers

The scope of COPE Administrators/Providers CE enterprise varies from for-profit to non-profit at the local, state/provincial, regional or national level.


## Scope of Companies Offering COPE Accredited CE



Non-Profit Companies		For Profit Companies	
Local	2	Local	36
State/Provincial	99	State/Provincial	246
Regional	1	Regional	18
National	1	National	25
Total Non-Profit	104	Total For Profit	325

# COPE Diversity of Companies

The COPE accreditation system is very diverse with the types of companies offering COPE Accredited CE ranging from state/provincial optometric associations to group optometric/ophthalmic practices, hospital/healthcare systems, and optometry/medical schools.




2024 COPE Administrator/Provider Company Type	Number
Business Consulting	5
CE Company	69
Foundation	9
Hospital/Healthcare System	7
Local Optometric Association	26
State/National Membership Organization	29
National Optometric Association	10
Group Optometric/Ophthalmic Practice	192
Government/Other	8
Optometry/Medical School	36
State/Provincial Optometric Association	38
<b>Total</b>	<b>429</b>

# COPE and Joint Accreditation

COPE also participates in the Joint Accreditation for Interprofessional Continuing Education™ collaborative. Joint Accreditation (JA) is a program developed through a collaboration by the Accreditation Council for Continuing Medical Education (ACCME®), the Accreditation Council for Pharmacy Education (ACPE®), and the American Nurses Credentialing Center (ANCC®). The program enables organizations to receive simultaneous accreditation for providing CE across multiple healthcare professions through a single application, unified accreditation criteria and standards, and fee structure. Jointly accredited providers are authorized to award CE credit to the following professions: athletic trainers, dentists, dietitians, nurses, optometrists, physician associates/physician assistants (PAs), pharmacists, physicians, psychologists, and social workers. More information on the Joint Accreditation collaborative may be found at <https://jointaccreditation.org/>.

COPE joined Joint Accreditation in 2018 as one of the first associate member accreditor organizations to provide optometrists with team-based continuing education opportunities, raise awareness among other healthcare professionals about optometry's role within the broader interprofessional healthcare system, and ultimately promote improved patient care and outcomes. Currently, 26 jointly accredited CE providers offer COPE credit. The type of company participating in Joint Accreditation with COPE in 2024 are shown below.

2024 Jointly Accredited Provider Company Type	Number
CE Company	16
Government	2
Hospital/Healthcare System	4
Medical School	4
<b>Total</b>	<b>26</b>







## **Modernization Efforts at NBEO: Information Technology and New Expanded Testing Center**

*Released: March 3, 2025*

As the optometric profession evolves, the National Board of Examiners in Optometry (NBEO®) is committed to maintaining high standards to meet current and future needs. To support this, we are investing significant time and resources to strengthen our technological and physical infrastructure.

### **Information Technology Modernization**

This transition began in 2022, when we performed a thorough review of our systems and started planning updates to our information technology infrastructure. Since 2008, NBEO has used a customized Enterprise Resource Planning (ERP) software called Optometric Examination Database Information System (OEDIS). As a result of our information technology modernization efforts, we will replace and rebuild OEDIS to provide candidates with a more reliable and efficient software throughout the examination process. This work will also enhance the experience of other stakeholder groups, including regulatory boards, schools and colleges of optometry, and NBEO subject matter experts. As you can imagine, replacing our entire technological backbone is complicated, and cannot be done overnight.

Fortunately, this transition is already under way, and you may have already noticed some improvements. In December 2023, we launched a new registration system to enhance the candidate experience by allowing us to serve more concurrent users during peak registrations, and we also streamlined the payment process. Registration sets the tone for candidates' exam experience, and we felt this was an important place to start.

Additionally, we built a new application for the Part III Patient Encounters and Performance Skills (PEPS®) Examination. This allows candidates to experience a clean, more modern exam format that balances clinical authenticity and the standardization necessary for a high stakes performance examination. The Part III PEPS exam was designed in a custom software solution independent from the OEDIS application. A critical component of our new

application has been making the examination a more true-to-life experience for our candidates. For this reason, we created an electronic health records database reflective of cases that doctors of optometry encounter in real optometric practice. Candidates are tested with cases from this database as part of their examination to diagnose and treat patients. This successful software transition is the foundation for improvements to other NBEO examinations.

Another major benefit of this modernization process will be the creation of a more automated system for scoring exams and publishing scores. As we have recently communicated [here](#), the exam scoring process is thorough and complex. This process is necessary to ensure that every candidate receives a fair assessment of their knowledge, skills, and abilities, no matter when they take their examination. While this commitment to fairness lengthens the scoring process, this new software will create a more efficient score publishing process.

In the coming year, our software solutions will be fully integrated, bringing increased efficiency to our registration and scoring process. In addition, our legacy software, OEDIS, is planned to be decommissioned from all uses by the end of 2026 to make way for more efficient replacement software.

Over the course of the next two years, NBEO will continue this modernization process. This year we expect to complete the following enhancements:

- Further expansions of the Part III PEPS testing system to allow for twice as many candidates to simultaneously perform the exam
- Improved integration with necessary software programs
- Candidate management system upgrades to simplify our exam registration and score publishing process
- In 2026, we plan to continue this transition with the following improvements:
  - Expanding improvements to each of the following exams:
    - Part I Applied Basic Science (ABS®)
    - Part II Patient Assessment & Management and Treatment and Management of Ocular Disease (PAM®/TMOD®)
    - Injections Skill Examination (ISE®)
    - Laser and Surgical Procedures Examination (LSPE®)
    - Online State Law Exams (OSLE®)
    - Advanced Competence in Medical Optometry (ACMO®)
  - Developing and launching an elevated data portal for candidates, schools and colleges of optometry, and regulatory boards.



We will provide updates as these changes are made so candidates and stakeholders can see and understand how these changes will improve their experience.

### **Increasing Testing Capacity**

Our commitment to modernizing NBEO extends beyond an updated information technology infrastructure. We have secured a new office and testing location in Charlotte that will double our testing capacity for the Part III Patient Encounters and Performance Skills (PEPS) Examination, ensuring more candidates obtain their preferred choice for date and time. In addition, the new location will have a dedicated Laser and Surgical Procedures Examination and Injections Skill Examination suite which can operate simultaneously with the Part III PEPS examination.

NBEO rigorously explored alternate location options, considering other cities and satellite testing locations. All other options, including staying in our current location, would significantly increase costs. In fact, NBEO expects this new location to generate approximately \$4 million in savings over the next decade. Those savings will enable NBEO to contain costs in its examination process.

The new NBEO National Center of Clinical Testing in Optometry will be located at 7910 Microsoft Way, Charlotte, North Carolina 28273 and will begin hosting examination candidates beginning August 2025.

We are excited about the changes ahead for NBEO and the positive impact they will have on candidates and the public we serve. If you have any questions about the information technology updates or our new testing center, please contact us at [nbeo@optometry.org](mailto:nbeo@optometry.org).

**About NBEO** — Established in 1951, NBEO is an independent, non-governmental, non-profit organization whose examinations are universally accepted for optometric licensure in the United States and accepted internationally. NBEO's mission is to protect the public by developing, administering, scoring, and reporting results of valid examinations that assess competency in optometry.

JOSH GREEN, M.D.  
GOVERNOR  
KE KIA'ĀINA



GOV. MSG. NO. 1376

EXECUTIVE CHAMBERS  
KE KE'ENA O KE KIA'ĀINA

July 2, 2025

The Honorable Ronald D. Kouchi  
President of the Senate,  
and Members of the Senate  
Thirty-Third State Legislature  
State Capitol, Room 409  
Honolulu, Hawai'i 96813

The Honorable Nadine Nakamura  
Speaker, and Members of the  
House of Representatives  
Thirty-Third State Legislature  
State Capitol, Room 431  
Honolulu, Hawai'i 96813

Aloha President Kouchi, Speaker Nakamura, and Members of the Legislature:

This is to inform you that on July 2, 2025, the following bill was signed into law:

S.B. NO. 1373, S.D. 2,  
H.D. 2, C.D. 1

RELATING TO ADMINISTRATIVE LICENSURE  
ACTIONS AGAINST SEX OFFENDERS.  
**ACT 273**

Mahalo,

A handwritten signature in black ink that reads "Josh Green M.D.".

Josh Green, M.D.  
Governor, State of Hawai'i

1 consumer affairs from pursuing disciplinary action based on any  
2 cause other than the overturned conviction.

3 (f) Any final order of discipline taken pursuant to this  
4 section shall be a matter of public record.

5 (g) The director of commerce and consumer affairs shall  
6 not restore, renew, or otherwise reinstate the license of a  
7 person under any of the following circumstances:

8 (1) The person has been required to register as a sex  
9 offender pursuant to chapter 846E, regardless of  
10 whether the conviction has been appealed; and

11 (2) The person engaged in the offense with a patient or  
12 client, or with a former patient or client if the  
13 relationship was terminated primarily for the purpose  
14 of committing the offense."

15 SECTION 21. Chapter 459, Hawaii Revised Statutes, is  
16 amended by adding a new section to be appropriately designated  
17 and to read as follows:

18 **"§459- Revocation of license or denial of application to**  
19 **renew, restore, or reinstate a license based on conviction**  
20 **requiring registration as a sex offender; conditions. (a)**  
21 Notwithstanding any law to the contrary, the board shall

**S.B. NO.** 1373  
S.D. 2  
H.D. 2  
C.D. 1

1 automatically revoke a license or deny an application to renew,  
2 restore, or reinstate a license under either of the following  
3 circumstances:

4       (1) The licensee has been convicted in any court in or  
5       outside of this State of any offense that, if  
6       committed or attempted in this State, based on the  
7       elements of the convicted offense, would have been  
8       punishable as one or more of the offenses described in  
9       chapter 846E; or

10       (2) The licensee has been required to register as a sex  
11       offender pursuant to chapter 846E, regardless of  
12       whether the related conviction has been appealed.

13       (b) The board shall notify the licensee of the license  
14 revocation or denial of application to renew, restore, or  
15 reinstate the license and of the right to elect to have a  
16 hearing as provided in subsection (c).

17       (c) Upon revocation of the license or denial of an  
18 application to renew, restore, or reinstate, the licensee may  
19 file a written request for a hearing with the board within ten  
20 days of the notice. The hearing shall be held within thirty



1 days of the revocation or denial. The proceeding shall be  
2 conducted in accordance with chapter 91.

3 (d) For the purposes of enforcement of this section, a  
4 plea or verdict of guilty, or a conviction after a plea of nolo  
5 contendere, shall be deemed a conviction. The record of  
6 conviction shall be conclusive evidence of the fact that the  
7 conviction occurred.

8 (e) If the related conviction of the license holder is  
9 overturned upon appeal, the revocation or denial ordered  
10 pursuant to this section shall automatically cease. Nothing in  
11 this subsection shall prohibit the board from pursuing  
12 disciplinary action based on any cause other than the overturned  
13 conviction.

14 (f) Any final order of discipline taken pursuant to this  
15 section shall be a matter of public record.

16 (g) The board shall not restore, renew, or otherwise  
17 reinstate the license of a person under any of the following  
18 circumstances:

19 (1) The person has been required to register as a sex  
20 offender pursuant to chapter 846E, regardless of  
21 whether the conviction has been appealed; and



S.B. NO. 1373  
S.D. 2  
H.D. 2  
C.D. 1

1       (2) The person engaged in the offense with a patient or  
2       client, or with a former patient or client if the  
3       relationship was terminated primarily for the purpose  
4       of committing the offense."

5       SECTION 22. Chapter 461, Hawaii Revised Statutes, is  
6       amended by adding a new section to be appropriately designated  
7       and to read as follows:

8       "§461-     Revocation of license or denial of application to  
9       renew, restore, or reinstate a license based on conviction  
10       requiring registration as a sex offender; conditions. (a)  
11       Notwithstanding any law to the contrary, the board shall  
12       automatically revoke a license or deny an application to renew,  
13       restore, or reinstate a license under either of the following  
14       circumstances:

15       (1) The licensee has been convicted in any court in or  
16       outside of this State of any offense that, if  
17       committed or attempted in this State, based on the  
18       elements of the convicted offense, would have been  
19       punishable as one or more of the offenses described in  
20       chapter 846E; or

